{"FullStudiesResponse": {"APIVrs": "1.01.05", "DataVrs": "2023:05:12 00:01:11.028", "Expression": "retinitis pigmentosa OR progressive pigmentary retinopathy OR rod-cone dystrophy OR RP", "NStudiesAvail": 452005, "NStudiesFound": 4642, "MinRank": 1, "MaxRank": 10, "NStudiesReturned": 10, "FullStudies": [{"Rank": 1, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT04763369", "OrgStudyIdInfo": {"OrgStudyId": "JB&RSC-02"}, "Organization": {"OrgFullName": "Jinnah Burn and Reconstructive Surgery Centre, Lahore", "OrgClass": "OTHER_GOV"}, "BriefTitle": "Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)", "OfficialTitle": "Investigation of Therapeutic Efficacy and Safety of Umbilical Cord Derived Mesenchymal Stem Cells (UMSCs) for the Management of Retinitis Pigmentosa (RP)"}, "StatusModule": {"StatusVerifiedDate": "February 2021", "OverallStatus": "Unknown status", "LastKnownStatus": "Recruiting", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "February 2021", "StartDateType": "Anticipated"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "May 2022", "PrimaryCompletionDateType": "Anticipated"}, "CompletionDateStruct": {"CompletionDate": "June 2022", "CompletionDateType": "Anticipated"}, "StudyFirstSubmitDate": "February 6, 2021", "StudyFirstSubmitQCDate": "February 18, 2021", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "February 21, 2021", "StudyFirstPostDateType": "Actual"}, "LastUpdateSubmitDate": "February 18, 2021", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "February 21, 2021", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Principal Investigator", "ResponsiblePartyInvestigatorFullName": "Prof. Dr. Sheikh Riazuddin", "ResponsiblePartyInvestigatorTitle": "Distinguished National Professor", "ResponsiblePartyInvestigatorAffiliation": "Jinnah Burn and Reconstructive Surgery Centre, Lahore"}, "LeadSponsor": {"LeadSponsorName": "Jinnah Burn and Reconstructive Surgery Centre, Lahore", "LeadSponsorClass": "OTHER_GOV"}, "CollaboratorList": {"Collaborator": [{"CollaboratorName": "The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township Lahore.", "CollaboratorClass": "UNKNOWN"}, {"CollaboratorName": "Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.", "CollaboratorClass": "UNKNOWN"}]}}, "OversightModule": {"OversightHasDMC": "Yes", "IsFDARegulatedDrug": "No", "IsFDARegulatedDevice": "No"}, "DescriptionModule": {"BriefSummary": "Retinitis pigmentosa (RP) is the most common hereditary retinal disorder (accounts for 20% of children attending blind schools in Pakistan) which causes degeneration of rod and cone photoreceptors. Rods and cones largely depend on the retinal pigment epithelium for their proper functioning. Various growth factors and their receptors are present in retinal epithelium and a number of genes are responsible for the production of these growth factors. Genetic mutation in any of these genes causes retinal degeneration by progressive loss of retinal pigment epithelium and photoreceptors. The disease initially starts with night blindness and leads to the loss of central vision and eventually total blindness. To date, there is no definitive cure for patients suffering from RP. Recently, stem cell based therapies have shown great promise for the management of RP. It is well documented that umbilical cord derived mesenchymal stem cells (UMSCs) have the ability to release various paracrine and immunomodulatory factors that are similar to those synthesized by retinal pigment epithelium. Multiple routes including systemic (intravenous) and localized (subretinal, intravitreal, suprachoroidal and sub-tenon) have been employed to administer UMSCs for the management of RP. It is important to note that deep sub-tenon region (space between the sclera and the conjunctiva) acts as both natural culture medium for cells and as immune privileged site because of avascularity of the region. It has been reported that the injection of UMSCs in sub-tenon space of human subjects have improved the visual acuity even after 1 year post-injection. In addition, the injection of UMSCs in suprachoroidal space enhances the entry of growth factors released by the cells into choroidal flow and maintain the constant growth factors secretion to the choroidal and retinal tissues. Limoli and colleagues were the first to report the suprachoroidal administration of cells being the safe mode of cell delivery with no complications. The present study is aimed to investigate the safety and therapeutic efficacy of UMSC injection employing two different routes (sub-tenon injection versus suprachoroidal injection) for the treatment of RP in human subjects.", "DetailedDescription": "Isolation and characterization of human umbilical cord derived mesenchymal stem cells (UMSCs): The culturing and characterization of UMSCs will be performed as documented by Ali and colleagues. Briefly, human umbilical cord tissues along with informed consent forms will be collected from COVID-19- and hepatitis B, C virus-negative women with healthy pregnancies during the Cesarean Section surgery after completion of gestation period. The umbilical cord tissue will be transported in sterile 1x phosphate-buffered saline (PBS) containing penicillin and streptomycin on ice. In the biosafety cabinet, the cord will be washed with 4-5 changes of sterile 1x PBS and placed in a Petri plate with 15ml PBS. The cord will then gently scrap with a surgical blade to remove any dead cells. A 9 cm umbilical cord will be cut into three equal pieces and wash thoroughly to remove blood clots, umbilical cord arteries, and veins. Segments will be washed three times with PBS and minced. The minced pieces will be incubated in 17.5ml of collagenase solution (201 U/ml collagenase type I in serum-free DMEM-HG) in a 50ml conical tube for ~3 hrs in an incubator at 5% CO2, 95% humidity at 37oC. After ~3 hrs, the digested lysate will be passed through strainer and will be diluted three times with 1x PBS. Following centrifugation, the cells will be seeded into two T-25cm2 flasks and will be placed in an incubator at 5% CO2, 95% humidity at 37o C. The flasks will be fed with fresh media (DMEM-HG supplemented with 20% FBS and 1% antibiotic solution) every third day. At around day 18, cells will reach up to 85% confluency and will be transferred in two T-75cm2 flasks with media replaced at alternate days. UMSCs at P3 will be characterized using different specific antibodies. Cells at P3 will be employed for injection in RP patients."}, "ConditionsModule": {"ConditionList": {"Condition": ["Retinitis Pigmentosa (RP)"]}, "KeywordList": {"Keyword": ["Retinitis pigmentosa", "Stem cells treatment"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 2"]}, "DesignInfo": {"DesignAllocation": "Randomized", "DesignInterventionModel": "Parallel Assignment", "DesignInterventionModelDescription": "Group 1: Five (5) subjects will be treated by injecting UMSCs in sub-tenon space of eye.\n\nGroup 2: Five (5) subjects will be treated by suprachoroidal injection of UMSCs .\n\nFrom two subjects in group 1 & 2 will not be treated 24 hrs apart. Patients will be randomized in a 1:1 ratio (Sub-tenon injection of UMSCs : Suprachoroidal injection of UMSCs).\n\nNote: In total, twenty five patients will be subjected to cell injection for each of group 1 & 2.", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "50", "EnrollmentType": "Anticipated"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "Sub-tenon injection group", "ArmGroupType": "Experimental", "ArmGroupDescription": "In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa"]}}, {"ArmGroupLabel": "Suprachoroidal injection group", "ArmGroupType": "Experimental", "ArmGroupDescription": "A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Biological", "InterventionName": "Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa", "InterventionDescription": "Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Sub-tenon injection group"]}}, {"InterventionType": "Biological", "InterventionName": "Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa", "InterventionDescription": "Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Suprachoroidal injection group"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Evaluation of safety related adverse ocular events including immune response", "PrimaryOutcomeDescription": "No significant side effects in stem cell treated subjects", "PrimaryOutcomeTimeFrame": "Baseline to day 360"}, {"PrimaryOutcomeMeasure": "Ophthalmic examination for best-corrected visual acuity (BCVA) using early treatment of diabetic retinopathy study (ETDRS) chart", "PrimaryOutcomeDescription": "Change in best corrected visual acuity (BCVA)", "PrimaryOutcomeTimeFrame": "Baseline to day 360"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Measurement of electrical activity/function of retina using Electroretinography (ERG) test", "SecondaryOutcomeDescription": "Change in electrical response/function of various cell types of retina", "SecondaryOutcomeTimeFrame": "Baseline to day 360"}, {"SecondaryOutcomeMeasure": "Evaluation of outer retinal thickness using Optical Coherence Tomography (OCT) imaging test", "SecondaryOutcomeDescription": "Alteration in retinal thickness", "SecondaryOutcomeTimeFrame": "Baseline to day 360"}, {"SecondaryOutcomeMeasure": "Examination of retinal damage by Fundus Photography", "SecondaryOutcomeDescription": "Change in retinal Fundus image", "SecondaryOutcomeTimeFrame": "Baseline to day 360"}, {"SecondaryOutcomeMeasure": "Evaluation of visual field sensitivity using perimeter", "SecondaryOutcomeDescription": "Change in visual field sensitivity", "SecondaryOutcomeTimeFrame": "Baseline to day 360"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nPatients who will be voluntarily participated for UMSCs injection for the treatment of RP.\nPatients who will be able to adhere to the study follow-up and protocol requirements.\nIndividuals with age ranges from 18 years to 70 years will be included.\nPatients with best corrected visual acuity (BCVA) from 50 letters to 110 letters or <20/50 in the ETDRS chart testing (Topcon CC-100 XP, Japan).\nMean deviation values ranging between -33.0 and - 5.0 dB with compass visual field analysis (threshold 24-2, Sita Standard, Stimulus 3-white).\nDiagnosis of any phenotypic or genotypic variation of RP, confirmed by clinical history, fundus appearance, visual field, electroretinogram and genetic mutation analysis.\n\nExclusion Criteria:\n\nPresence of cataracts or other media opacity that might affect the visual field, mean deviation, or electroretinogram recordings.\nPresence of another ocular disease except RP (i.e., uveitis, strabismus, glaucoma) that causes visual field and optic disc changes.\nPresence of any systemic disorder that may affect visual functions. This includes diabetes, neurological disorders, and uncontrolled systemic hypertension.\nSmokers will be excluded from the study.\nIndividuals who underwent ocular surgery except cataract extraction will be considered as excluded.", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "18 Years", "MaximumAge": "70 Years", "StdAgeList": {"StdAge": ["Adult", "Older Adult"]}}, "ContactsLocationsModule": {"CentralContactList": {"CentralContact": [{"CentralContactName": "Sheikh Riazuddin, PhD", "CentralContactRole": "Contact", "CentralContactPhone": "+9242935164422", "CentralContactEMail": "riazuddin@aimrc.org"}, {"CentralContactName": "Muhammad Ali, PhD", "CentralContactRole": "Contact", "CentralContactPhone": "+923218429448", "CentralContactEMail": "riazuddin@aimrc.org"}]}, "OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Sheikh Riazuddin, PhD", "OverallOfficialAffiliation": "Jinnah Burn & Reconstructive Surgery Center, Lahore", "OverallOfficialRole": "Principal Investigator"}, {"OverallOfficialName": "Zaheer-ud-Din A Qazi, consultant", "OverallOfficialAffiliation": "The Layton Rahmatullah Benevolent Trust (LRBT)", "OverallOfficialRole": "Principal Investigator"}]}, "LocationList": {"Location": [{"LocationFacility": "Stem Cell laboratory, Jinnah Burn & Reconstructive Surgery Centre", "LocationStatus": "Recruiting", "LocationCity": "Lahore", "LocationState": "Punjab", "LocationZip": "54550", "LocationCountry": "Pakistan", "LocationContactList": {"LocationContact": [{"LocationContactName": "Muhammad Ali, PhD", "LocationContactRole": "Contact", "LocationContactPhone": "+923218429448", "LocationContactEMail": "riazuddin@aimrc.org"}]}}]}}, "ReferencesModule": {"ReferenceList": {"Reference": [{"ReferencePMID": "32953582", "ReferenceType": "background", "ReferenceCitation": "Kahraman NS, Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial. Int J Ophthalmol. 2020 Sep 18;13(9):1423-1429. doi: 10.18240/ijo.2020.09.14. eCollection 2020."}, {"ReferencePMID": "21987686", "ReferenceType": "background", "ReferenceCitation": "Azam M, Collin RW, Malik A, Khan MI, Shah ST, Shah AA, Hussain A, Sadeque A, Arimadyo K, Ajmal M, Azam A, Qureshi N, Bokhari H, Strom TM, Cremers FP, Qamar R, den Hollander AI. Identification of novel mutations in Pakistani families with autosomal recessive retinitis pigmentosa. Arch Ophthalmol. 2011 Oct;129(10):1377-8. doi: 10.1001/archophthalmol.2011.290. No abstract available."}, {"ReferencePMID": "31931872", "ReferenceType": "background", "ReferenceCitation": "Ozmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Res Ther. 2020 Jan 13;11(1):25. doi: 10.1186/s13287-020-1549-6."}, {"ReferencePMID": "32787913", "ReferenceType": "background", "ReferenceCitation": "Ozmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results. Stem Cell Res Ther. 2020 Aug 12;11(1):353. doi: 10.1186/s13287-020-01870-w."}, {"ReferencePMID": "25546695", "ReferenceType": "background", "ReferenceCitation": "Limoli PG, Vingolo EM, Morales MU, Nebbioso M, Limoli C. Preliminary study on electrophysiological changes after cellular autograft in age-related macular degeneration. Medicine (Baltimore). 2014 Dec;93(29):e355. doi: 10.1097/MD.0000000000000355."}, {"ReferenceType": "background", "ReferenceCitation": "Ali M, Mehmood A, Tarar MN, Nawaz Z, Riazuddin SA, Khan A, Riazuddin S. Efficacy of intravenous infusions of UC-derived MSCs for the treatment of COVID-19: A structured summary of a phase II double blinded, randomized controlled clinical trial. Preprint from Research Square, 28 Oct 2020. DOI: 10.21203/rs.3.rs-92995/v2"}]}}, "IPDSharingStatementModule": {"IPDSharing": "Undecided"}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000012173", "ConditionMeshTerm": "Retinitis"}, {"ConditionMeshId": "D000012174", "ConditionMeshTerm": "Retinitis Pigmentosa"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000012164", "ConditionAncestorTerm": "Retinal Diseases"}, {"ConditionAncestorId": "D000005128", "ConditionAncestorTerm": "Eye Diseases"}, {"ConditionAncestorId": "D000015785", "ConditionAncestorTerm": "Eye Diseases, Hereditary"}, {"ConditionAncestorId": "D000058499", "ConditionAncestorTerm": "Retinal Dystrophies"}, {"ConditionAncestorId": "D000012162", "ConditionAncestorTerm": "Retinal Degeneration"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M14160", "ConditionBrowseLeafName": "Retinitis", "ConditionBrowseLeafAsFound": "Retinitis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14161", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14151", "ConditionBrowseLeafName": "Retinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M7423", "ConditionBrowseLeafName": "Eye Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M17491", "ConditionBrowseLeafName": "Eye Diseases, Hereditary", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M28260", "ConditionBrowseLeafName": "Retinal Dystrophies", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M14149", "ConditionBrowseLeafName": "Retinal Degeneration", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T4945", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC11", "ConditionBrowseBranchName": "Eye Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}}}}, {"Rank": 2, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT03063021", "OrgStudyIdInfo": {"OrgStudyId": "IRB00103296"}, "Organization": {"OrgFullName": "Johns Hopkins University", "OrgClass": "OTHER"}, "BriefTitle": "The FIGHT-RP1 Study", "OfficialTitle": "A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)", "Acronym": "FIGHT-RP1"}, "StatusModule": {"StatusVerifiedDate": "December 2021", "OverallStatus": "Completed", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "February 15, 2017", "StartDateType": "Actual"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "February 11, 2019", "PrimaryCompletionDateType": "Actual"}, "CompletionDateStruct": {"CompletionDate": "February 11, 2019", "CompletionDateType": "Actual"}, "StudyFirstSubmitDate": "February 16, 2017", "StudyFirstSubmitQCDate": "February 20, 2017", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "February 24, 2017", "StudyFirstPostDateType": "Actual"}, "LastUpdateSubmitDate": "September 15, 2022", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "September 19, 2022", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Johns Hopkins University", "LeadSponsorClass": "OTHER"}}, "OversightModule": {"IsFDARegulatedDrug": "Yes", "IsFDARegulatedDevice": "No"}, "DescriptionModule": {"BriefSummary": "Retinitis Pigmentosa (RP) is a devastating eye disease and at present there are no known treatment options that can alter the rate of vision loss. In a series of studies in animal models, the effects of exposing cones in the periphery of the retina to a large excess of oxygen results in progressive oxidative damage to cone photoreceptors and cone cell death. Compared to control patients, those with RP showed significant reduction in the reduced to oxidized glutathione ratio (GSH/GSSG) in aqueous humor and a significant increase in protein carbonyl content. This demonstration of oxidative stress and oxidative damage in the eyes of patients with RP, suggests that oxidative damage-induced cone cell death in animal models of RP may translate to humans with RP and support the hypotheses that (1) potent antioxidants will promote cone survival and function in patients with RP and (2) aqueous GSH/GSSG ratio and carbonyl content on proteins provide useful biomarkers of disease activity in this patient population. Orally administered N-Acetylcysteine (NAC) has been found to be a particularly effective antioxidant that promotes prolonged cone survival and maintenance of cone function in a mouse model of RP. There is good rationale to test the effect of NAC in patients with RP. The first step is to test different dosing regimens to identify the lowest dose that is able to restore aqueous GSH/GSSG ratio and reduce carbonyl adducts on aqueous proteins.\n\nIn patients with Idiopathic Pulmonary Fibrosis, polymorphisms within the TOLLIP gene were found to influence outcomes of NAC-treated patients. The product of the TOLLIP gene, toll-interacting protein, is an inhibitory adaptor protein downstream of toll-like receptors, mediators of innate and adaptive immunity. The identification of the influence of TOLLIP polymorphisms on the effect of NAC in Idiopathic Pulmonary Fibrosis provides the rationale for collecting DNA and genotyping the same single nucleotide polymorphisms (SNPs) in the current trial. In addition to this candidate gene genetic analysis, patient RNA will be collected and banked for future transcriptome analysis. The rationale for this is to identify gene expression changes that modify disease progression in RP. There is substantial variability in the rate of progression among patients with RP. A patient who loses all vision early in life can have a sibling with the same mutation who maintains vision into advanced age. This suggests that modifier genes can have a major impact on cone survival. This study will test the hypothesis that the level of expression of gene products that contribute to the antioxidant defense system may influence cone cell death and hence the rate of loss of visual field. It is also possible that gene expression differences may contribute to differences in response to NAC. For these reasons collecting RNA samples from patients will allow next-generation sequencing in the future to understand the transcriptome background on which the study intervention has been performed."}, "ConditionsModule": {"ConditionList": {"Condition": ["Retinitis Pigmentosa"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 1"]}, "DesignInfo": {"DesignAllocation": "Non-Randomized", "DesignInterventionModel": "Parallel Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "30", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)", "ArmGroupType": "Experimental", "ArmGroupDescription": "Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) in the aqueous.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: N-Acetyl Cysteine (NAC)"]}}, {"ArmGroupLabel": "Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)", "ArmGroupType": "Experimental", "ArmGroupDescription": "Subjects with RP who don't have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: N-Acetyl Cysteine (NAC)"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Drug", "InterventionName": "N-Acetyl Cysteine (NAC)", "InterventionDescription": "Oral tablets of N-acetyl-cysteine", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)", "Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Assessment of safety and tolerability of N-Acetylcysteine including incidence and severity of systemic and ocular adverse events (AEs) and changes from baseline vital signs and physical examination.", "PrimaryOutcomeDescription": "Assessment of safety and tolerability of N-Acetylcysteine including incidence and severity of systemic and ocular adverse events (AEs) and changes from baseline vital signs and physical examination.", "PrimaryOutcomeTimeFrame": "Up to 10 months"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 1 month after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "1 month after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 2 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "2 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 3 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "3 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 4 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "4 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 5 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "5 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 6 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "6 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 7 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "7 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 8 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "8 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 9 months after initiation of N-Acetylcysteine .", "SecondaryOutcomeTimeFrame": "9 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline best corrected visual acuity (BCVA) 6 months after initiation of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "6 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline central retinal sensitivity by microperimetry 3 months after initiation of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "3 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline central retinal sensitivity by microperimetry 6 months after initiation of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "6 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline central retinal sensitivity by microperimetry 9 months after initiation of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "9 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline ellipsoid zone (EZ) width by spectral domain optical coherence tomography (SD-OCT) 6 months after initiation of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "6 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline aqueous levels of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "1, 2, 3, 4, 5, 6, 7, 8, and 9 months after initiation of N-Acetylcysteine"}, {"SecondaryOutcomeMeasure": "Change from baseline plasma levels of N-Acetylcysteine", "SecondaryOutcomeTimeFrame": "3 and 6 months after initiation of N-Acetylcysteine"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nAll subjects must meet the following criteria to be eligible for study entry:\n\nSigned informed consent and authorization of use and disclosure of protected health information\nAge >18 years\nPatients diagnosed with RP by the investigators, based on clinical phenotype and diagnostic tests\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be ineligible for study entry:\n\nPatients with concurrent retinal pathologies that result in vision loss, including but not limited to retinal vein occlusion, diabetic retinopathy and neovascular age-related macular degeneration. If one eye does not have any retinal pathology other than RP, it may be enrolled in the study.\nPatients with uncontrolled arterial hypertension defined as diastolic blood pressure > 95 mm Hg or systolic blood pressure > 160 mm Hg despite medical therapy.", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "18 Years", "StdAgeList": {"StdAge": ["Adult", "Older Adult"]}}, "ContactsLocationsModule": {"LocationList": {"Location": [{"LocationFacility": "Wilmer Eye Institute, Johns Hopkins", "LocationCity": "Baltimore", "LocationState": "Maryland", "LocationZip": "21287", "LocationCountry": "United States"}]}}, "ReferencesModule": {"ReferenceList": {"Reference": [{"ReferencePMID": "31805012", "ReferenceType": "derived", "ReferenceCitation": "Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, Lu L, Wall GM, Singh MS, Kong X. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Invest. 2020 Mar 2;130(3):1527-1541. doi: 10.1172/JCI132990."}]}}, "IPDSharingStatementModule": {"IPDSharing": "Undecided"}}, "DocumentSection": {"LargeDocumentModule": {"LargeDocList": {"LargeDoc": [{"LargeDocTypeAbbrev": "Prot_SAP", "LargeDocHasProtocol": "Yes", "LargeDocHasSAP": "Yes", "LargeDocHasICF": "No", "LargeDocLabel": "Study Protocol and Statistical Analysis Plan", "LargeDocDate": "April 12, 2018", "LargeDocUploadDate": "11/15/2021 17:06", "LargeDocFilename": "Prot_SAP_000.pdf"}, {"LargeDocTypeAbbrev": "ICF", "LargeDocHasProtocol": "No", "LargeDocHasSAP": "No", "LargeDocHasICF": "Yes", "LargeDocLabel": "Informed Consent Form", "LargeDocDate": "October 9, 2018", "LargeDocUploadDate": "11/15/2021 17:07", "LargeDocFilename": "ICF_001.pdf"}]}}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000012173", "ConditionMeshTerm": "Retinitis"}, {"ConditionMeshId": "D000012174", "ConditionMeshTerm": "Retinitis Pigmentosa"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000012164", "ConditionAncestorTerm": "Retinal Diseases"}, {"ConditionAncestorId": "D000005128", "ConditionAncestorTerm": "Eye Diseases"}, {"ConditionAncestorId": "D000015785", "ConditionAncestorTerm": "Eye Diseases, Hereditary"}, {"ConditionAncestorId": "D000058499", "ConditionAncestorTerm": "Retinal Dystrophies"}, {"ConditionAncestorId": "D000012162", "ConditionAncestorTerm": "Retinal Degeneration"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M14160", "ConditionBrowseLeafName": "Retinitis", "ConditionBrowseLeafAsFound": "Retinitis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14161", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14151", "ConditionBrowseLeafName": "Retinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M7423", "ConditionBrowseLeafName": "Eye Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M17491", "ConditionBrowseLeafName": "Eye Diseases, Hereditary", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M28260", "ConditionBrowseLeafName": "Retinal Dystrophies", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M14149", "ConditionBrowseLeafName": "Retinal Degeneration", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T4945", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC11", "ConditionBrowseBranchName": "Eye Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}, "InterventionBrowseModule": {"InterventionMeshList": {"InterventionMesh": [{"InterventionMeshId": "D000000111", "InterventionMeshTerm": "Acetylcysteine"}, {"InterventionMeshId": "C000030905", "InterventionMeshTerm": "N-monoacetylcystine"}]}, "InterventionAncestorList": {"InterventionAncestor": [{"InterventionAncestorId": "D000000998", "InterventionAncestorTerm": "Antiviral Agents"}, {"InterventionAncestorId": "D000000890", "InterventionAncestorTerm": "Anti-Infective Agents"}, {"InterventionAncestorId": "D000005100", "InterventionAncestorTerm": "Expectorants"}, {"InterventionAncestorId": "D000019141", "InterventionAncestorTerm": "Respiratory System Agents"}, {"InterventionAncestorId": "D000016166", "InterventionAncestorTerm": "Free Radical Scavengers"}, {"InterventionAncestorId": "D000000975", "InterventionAncestorTerm": "Antioxidants"}, {"InterventionAncestorId": "D000045504", "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"}, {"InterventionAncestorId": "D000020011", "InterventionAncestorTerm": "Protective Agents"}, {"InterventionAncestorId": "D000045505", "InterventionAncestorTerm": "Physiological Effects of Drugs"}, {"InterventionAncestorId": "D000000931", "InterventionAncestorTerm": "Antidotes"}]}, "InterventionBrowseLeafList": {"InterventionBrowseLeaf": [{"InterventionBrowseLeafId": "M2627", "InterventionBrowseLeafName": "Acetylcysteine", "InterventionBrowseLeafAsFound": "Examined", "InterventionBrowseLeafRelevance": "high"}, {"InterventionBrowseLeafId": "M244015", "InterventionBrowseLeafName": "N-monoacetylcystine", "InterventionBrowseLeafAsFound": "Pulp", "InterventionBrowseLeafRelevance": "high"}, {"InterventionBrowseLeafId": "M3466", "InterventionBrowseLeafName": "Antiviral Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M3366", "InterventionBrowseLeafName": "Anti-Infective Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M7395", "InterventionBrowseLeafName": "Expectorants", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M20290", "InterventionBrowseLeafName": "Respiratory System Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M3444", "InterventionBrowseLeafName": "Antioxidants", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M21022", "InterventionBrowseLeafName": "Protective Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M3402", "InterventionBrowseLeafName": "Antidotes", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "T4", "InterventionBrowseLeafName": "Cysteine", "InterventionBrowseLeafAsFound": "Attempt", "InterventionBrowseLeafRelevance": "high"}]}, "InterventionBrowseBranchList": {"InterventionBrowseBranch": [{"InterventionBrowseBranchAbbrev": "Infe", "InterventionBrowseBranchName": "Anti-Infective Agents"}, {"InterventionBrowseBranchAbbrev": "Resp", "InterventionBrowseBranchName": "Respiratory System Agents"}, {"InterventionBrowseBranchAbbrev": "All", "InterventionBrowseBranchName": "All Drugs and Chemicals"}, {"InterventionBrowseBranchAbbrev": "AA", "InterventionBrowseBranchName": "Amino Acids"}]}}}}}, {"Rank": 3, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT05246384", "OrgStudyIdInfo": {"OrgStudyId": "RP7214-2102"}, "Organization": {"OrgFullName": "Rhizen Pharmaceuticals SA", "OrgClass": "INDUSTRY"}, "BriefTitle": "Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia", "OfficialTitle": "A Phase I/Ib, Open-label Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214, a Dihydro-orotate Dehydrogenase (DHODH) Inhibitor, Administered Orally in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia"}, "StatusModule": {"StatusVerifiedDate": "October 2022", "OverallStatus": "Withdrawn", "WhyStopped": "Change in development plan", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "January 2023", "StartDateType": "Anticipated"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "December 2024", "PrimaryCompletionDateType": "Anticipated"}, "CompletionDateStruct": {"CompletionDate": "November 2025", "CompletionDateType": "Anticipated"}, "StudyFirstSubmitDate": "January 29, 2022", "StudyFirstSubmitQCDate": "February 8, 2022", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "February 18, 2022", "StudyFirstPostDateType": "Actual"}, "LastUpdateSubmitDate": "October 27, 2022", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "October 31, 2022", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Rhizen Pharmaceuticals SA", "LeadSponsorClass": "INDUSTRY"}}, "OversightModule": {"OversightHasDMC": "No", "IsFDARegulatedDrug": "No", "IsFDARegulatedDevice": "No"}, "DescriptionModule": {"BriefSummary": "This is a multi-center, open-label, non-randomized, two-part Phase I/Ib study of RP7214 in combination with azacitidine in patients with AML, MDS and CMML. Part I is a 3+3 dose-escalation study to identify the MTD/RP2D of RP7214 and azacitidine combination in patients with AML, MDS, and CMML. Part II is a dose-expansion study to evaluate the clinical activity and safety of RP7214 and azacitidine combination in AML."}, "ConditionsModule": {"ConditionList": {"Condition": ["Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Acute Myeloid Leukemia"]}, "KeywordList": {"Keyword": ["RP7214", "Dihydro-orotate Dehydrogenase (DHODH)"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 1", "Phase 2"]}, "DesignInfo": {"DesignAllocation": "Non-Randomized", "DesignInterventionModel": "Sequential Assignment", "DesignInterventionModelDescription": "open-label, non-randomized, two-part Phase I/Ib study", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "0", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "Part I (dose escalation) RP7214 + Azacitidine", "ArmGroupType": "Experimental", "ArmGroupDescription": "Participants will receive RP7214 orally in combination with Azacitidine in a 28-day cycle. The dose levels will be escalated until MTD/a recommended Phase 2 dose (RP2D) has been identified.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: RP7214"]}}, {"ArmGroupLabel": "Part II (dose expansion) RP7214 + Azacitidine", "ArmGroupType": "Experimental", "ArmGroupDescription": "Participants will receive RP7214 orally at the MTD/RP2D in combination with Azacitidine in a 28-day cycle.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: RP7214"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Drug", "InterventionName": "RP7214", "InterventionDescription": "RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Part I (dose escalation) RP7214 + Azacitidine", "Part II (dose expansion) RP7214 + Azacitidine"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of RP7214 in combination with azacitidine", "PrimaryOutcomeDescription": "The maximum tolerated dose will be defined as the highest dose tested in which a DLT is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels.", "PrimaryOutcomeTimeFrame": "28 days"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Tmax", "SecondaryOutcomeDescription": "Pharmacokinetics: Time to Reach Maximum Concentration (Tmax) of RP7214", "SecondaryOutcomeTimeFrame": "35 days"}, {"SecondaryOutcomeMeasure": "Objective Response Rate (ORR)", "SecondaryOutcomeDescription": "Defined as the percentage of patients who achieve Complete Remission (CR), Complete Remission with incomplete bone marrow recovery (CRi) and Partial Remission (PR)", "SecondaryOutcomeTimeFrame": "2 years"}, {"SecondaryOutcomeMeasure": "Clinical Benefit Rate (CBR)", "SecondaryOutcomeDescription": "Defined as the percentage of patients achieving a CR, CRi, PR and Stable Disease (SD) lasting for at least 8 weeks.", "SecondaryOutcomeTimeFrame": "2 years"}, {"SecondaryOutcomeMeasure": "Duration of Remission", "SecondaryOutcomeDescription": "Defined as the number of days from the date of first remission (CR, CRi, or PR) to the recurrence or Progressive Disease (PD)", "SecondaryOutcomeTimeFrame": "2 years"}, {"SecondaryOutcomeMeasure": "Percentage of patients requiring blood and/or platelet transfusions", "SecondaryOutcomeDescription": "Defined as number of patients requiring blood and/or platelet transfusions", "SecondaryOutcomeTimeFrame": "2 years"}, {"SecondaryOutcomeMeasure": "Cmax", "SecondaryOutcomeDescription": "Pharmacokinetics: Maximum Concentration (Cmax) of RP7214", "SecondaryOutcomeTimeFrame": "35 days"}, {"SecondaryOutcomeMeasure": "AUC", "SecondaryOutcomeDescription": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of RP7214", "SecondaryOutcomeTimeFrame": "35 days"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nPatient must sign informed consent.\nPatient should be \u2265 18 years of age.\n\nPatients who are candidates for treatment with azacitidine and present with one of the following:\n\na. Part I: Dose Escalation study i. Patient with histologically or cytologically confirmed relapsed/refractory AML as per World Health Organization (WHO) classification, 2016 'OR' ii. Newly diagnosed AML patients who are ineligible for intensive induction chemotherapy due to co-morbidity or other factors 'OR' iii. Intermediate-2 or high-risk MDS according to the International Prognostic Scoring System (IPSS) 'OR' iv. Chronic Myelomonocytic Leukemia (CMML) b. Part II: Dose Expansion study i. Newly diagnosed AML patients who are ineligible for intensive induction chemotherapy due to co-morbidity or other factors.\n\nPatient should have an Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.\nPatients must be amenable to serial bone marrow biopsies/aspirates and peripheral blood sampling as required by the protocol.\n\nExclusion Criteria:\n\nAny cancer-directed therapy taken (e.g., chemotherapy, immunotherapy, biologic therapy or an investigational drug) within 14 days or 5 half-lives, whichever is shorter, prior to C1D1. For radiation therapy, at least 60 days should elapse from prior Total Body Irradiation (TBI) and at least 14 days from local palliative radiation therapy.\nPatients with rapidly increasing peripheral blast counts (WBC count > 25,000/\u03bcL) while on hydroxyurea prior to C1D1.\nPatients with Acute Promyelocytic Leukemia (French American-British Class M3 AML).\nPatients on immunosuppressive therapy post autologous or allogeneic stem cell transplantation (ASCT or Allo-SCT) at the time of screening, or with clinically significant Graft-Versus-Host Disease (GVHD) in the opinion of the Investigator or has not recovered from transplant-associated toxicities prior to C1D1.\nPatient who discontinued prior therapy with DHODH inhibitors or azacitidine due to drug-related toxicity.\nEvidence of uncontrolled/progressing infection.\nPatients with immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or Disseminated Intravascular Coagulation (DIC).\nPresence of isolated extramedullary relapse.\nPregnant or lactating women", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "18 Years", "StdAgeList": {"StdAge": ["Adult", "Older Adult"]}}, "IPDSharingStatementModule": {"IPDSharing": "No"}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000007938", "ConditionMeshTerm": "Leukemia"}, {"ConditionMeshId": "D000007951", "ConditionMeshTerm": "Leukemia, Myeloid"}, {"ConditionMeshId": "D000015470", "ConditionMeshTerm": "Leukemia, Myeloid, Acute"}, {"ConditionMeshId": "D000011289", "ConditionMeshTerm": "Preleukemia"}, {"ConditionMeshId": "D000015479", "ConditionMeshTerm": "Leukemia, Myelomonocytic, Acute"}, {"ConditionMeshId": "D000015477", "ConditionMeshTerm": "Leukemia, Myelomonocytic, Chronic"}, {"ConditionMeshId": "D000054429", "ConditionMeshTerm": "Leukemia, Myelomonocytic, Juvenile"}, {"ConditionMeshId": "D000009190", "ConditionMeshTerm": "Myelodysplastic Syndromes"}, {"ConditionMeshId": "D000013577", "ConditionMeshTerm": "Syndrome"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000004194", "ConditionAncestorTerm": "Disease"}, {"ConditionAncestorId": "D000010335", "ConditionAncestorTerm": "Pathologic Processes"}, {"ConditionAncestorId": "D000009370", "ConditionAncestorTerm": "Neoplasms by Histologic Type"}, {"ConditionAncestorId": "D000009369", "ConditionAncestorTerm": "Neoplasms"}, {"ConditionAncestorId": "D000001855", "ConditionAncestorTerm": "Bone Marrow Diseases"}, {"ConditionAncestorId": "D000006402", "ConditionAncestorTerm": "Hematologic Diseases"}, {"ConditionAncestorId": "D000011230", "ConditionAncestorTerm": "Precancerous Conditions"}, {"ConditionAncestorId": "D000054437", "ConditionAncestorTerm": "Myelodysplastic-Myeloproliferative Diseases"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M15507", "ConditionBrowseLeafName": "Syndrome", "ConditionBrowseLeafAsFound": "Syndrome", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M10097", "ConditionBrowseLeafName": "Leukemia", "ConditionBrowseLeafAsFound": "Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M10107", "ConditionBrowseLeafName": "Leukemia, Myeloid", "ConditionBrowseLeafAsFound": "Myeloid Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M17279", "ConditionBrowseLeafName": "Leukemia, Myeloid, Acute", "ConditionBrowseLeafAsFound": "Acute Myeloid Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M26859", "ConditionBrowseLeafName": "Leukemia, Myelomonocytic, Juvenile", "ConditionBrowseLeafAsFound": "Chronic Myelomonocytic Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M13316", "ConditionBrowseLeafName": "Preleukemia", "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M11297", "ConditionBrowseLeafName": "Myelodysplastic Syndromes", "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M17284", "ConditionBrowseLeafName": "Leukemia, Myelomonocytic, Chronic", "ConditionBrowseLeafAsFound": "Chronic Myelomonocytic Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M17286", "ConditionBrowseLeafName": "Leukemia, Myelomonocytic, Acute", "ConditionBrowseLeafAsFound": "Myelomonocytic Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M11467", "ConditionBrowseLeafName": "Neoplasms by Histologic Type", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M4286", "ConditionBrowseLeafName": "Bone Marrow Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M8642", "ConditionBrowseLeafName": "Hematologic Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M13263", "ConditionBrowseLeafName": "Precancerous Conditions", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M11301", "ConditionBrowseLeafName": "Myeloproliferative Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M26860", "ConditionBrowseLeafName": "Myelodysplastic-Myeloproliferative Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T170", "ConditionBrowseLeafName": "Acute Graft Versus Host Disease", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T3995", "ConditionBrowseLeafName": "Myeloid Leukemia", "ConditionBrowseLeafAsFound": "Myeloid Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T182", "ConditionBrowseLeafName": "Acute Myeloid Leukemia", "ConditionBrowseLeafAsFound": "Acute Myeloid Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T188", "ConditionBrowseLeafName": "Acute Non Lymphoblastic Leukemia", "ConditionBrowseLeafAsFound": "Acute Myeloid Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T3174", "ConditionBrowseLeafName": "Juvenile Myelomonocytic Leukemia", "ConditionBrowseLeafAsFound": "Chronic Myelomonocytic Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T1310", "ConditionBrowseLeafName": "Chronic Myelomonocytic Leukemia", "ConditionBrowseLeafAsFound": "Chronic Myelomonocytic Leukemia", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T3993", "ConditionBrowseLeafName": "Myelodysplastic Syndromes", "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T1303", "ConditionBrowseLeafName": "Chronic Graft Versus Host Disease", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T1311", "ConditionBrowseLeafName": "Chronic Myeloproliferative Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T3994", "ConditionBrowseLeafName": "Myelodysplastic/myeloproliferative Disease", "ConditionBrowseLeafRelevance": "low"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC23", "ConditionBrowseBranchName": "Symptoms and General Pathology"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC04", "ConditionBrowseBranchName": "Neoplasms"}, {"ConditionBrowseBranchAbbrev": "BC15", "ConditionBrowseBranchName": "Blood and Lymph Conditions"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}, "InterventionBrowseModule": {"InterventionBrowseLeafList": {"InterventionBrowseLeaf": [{"InterventionBrowseLeafId": "M3825", "InterventionBrowseLeafName": "Azacitidine", "InterventionBrowseLeafRelevance": "low"}]}, "InterventionBrowseBranchList": {"InterventionBrowseBranch": [{"InterventionBrowseBranchAbbrev": "ANeo", "InterventionBrowseBranchName": "Antineoplastic Agents"}, {"InterventionBrowseBranchAbbrev": "All", "InterventionBrowseBranchName": "All Drugs and Chemicals"}]}}}}}, {"Rank": 4, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT01543906", "OrgStudyIdInfo": {"OrgStudyId": "RET RP 01"}, "Organization": {"OrgFullName": "QLT Inc.", "OrgClass": "INDUSTRY"}, "BriefTitle": "Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)", "OfficialTitle": "An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)"}, "StatusModule": {"StatusVerifiedDate": "December 2014", "OverallStatus": "Completed", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "February 2012"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "July 2014", "PrimaryCompletionDateType": "Actual"}, "CompletionDateStruct": {"CompletionDate": "August 2014", "CompletionDateType": "Actual"}, "StudyFirstSubmitDate": "February 17, 2012", "StudyFirstSubmitQCDate": "March 1, 2012", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "March 5, 2012", "StudyFirstPostDateType": "Estimate"}, "LastUpdateSubmitDate": "December 11, 2014", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "December 15, 2014", "LastUpdatePostDateType": "Estimate"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "QLT Inc.", "LeadSponsorClass": "INDUSTRY"}}, "OversightModule": {"OversightHasDMC": "No"}, "DescriptionModule": {"BriefSummary": "The purpose of this study is:\n\nTo evaluate whether 7-day treatment with oral QLT091001 can improve visual function in RP subjects with an autosomal dominant mutation in RPE65.\nTo evaluate duration of visual function improvement (if observed) in RP subjects with an autosomal dominant mutation in RPE65 after 7-day treatment with oral QLT091001.\nTo evaluate the safety of oral QLT091001 administered once daily for 7 days in RP subjects with an autosomal dominant mutation in RPE65."}, "ConditionsModule": {"ConditionList": {"Condition": ["Retinitis Pigmentosa (RP)"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 1"]}, "DesignInfo": {"DesignAllocation": "N/A", "DesignInterventionModel": "Single Group Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "5", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "QLT091001", "ArmGroupType": "Experimental", "ArmGroupDescription": "oral QLT091001 administered once daily for 7 days", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: QLT091001"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Drug", "InterventionName": "QLT091001", "InterventionDescription": "oral QLT091001 administered once daily for 7 days", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["QLT091001"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Visual field", "PrimaryOutcomeTimeFrame": "12 months"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Safety will be assessed by evaluating the following: adverse events, clinical laboratory results, ECG's and vital signs", "SecondaryOutcomeTimeFrame": "12 months"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nSubjects will have RP caused by an autosomal dominant mutation in RPE65, as diagnosed by an ocular geneticist or ophthalmologist.\nSubjects who have a best-corrected standard ETDRS visual acuity of 3 letters or better (20/800 Snellen equivalent) or visible photoreceptor outer segments on OCT/FAF.\n\nExclusion Criteria:\n\nSubjects with any clinically important abnormal physical finding at Screening.\nSubjects who have taken any prescription or investigational oral retinoid medication (e.g., Accutane/Roaccutane\u00ae or Soriatane/Neotigason\u00ae) within 6 months of Day 0 and subjects who did not tolerate their previous oral retinoid medication will be excluded regardless of the time of last exposure.\nSubjects with a history of diabetes or chronic hyperlipidemia, hepatitis, pancreatitis, or cirrhosis.\nSubjects who have taken any supplements containing \u226510,000 IU vitamin A within 60 days of Screening.", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "18 Years", "MaximumAge": "70 Years", "StdAgeList": {"StdAge": ["Adult", "Older Adult"]}}, "ContactsLocationsModule": {"OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Sushanta Mallick", "OverallOfficialAffiliation": "QLT Inc.", "OverallOfficialRole": "Study Director"}]}, "LocationList": {"Location": [{"LocationFacility": "Montreal Children's Hospital, McGill University Health Centre", "LocationCity": "Montreal", "LocationState": "Quebec", "LocationCountry": "Canada"}, {"LocationFacility": "Royal Victoria Eye and Ear Hospital", "LocationCity": "Dublin", "LocationCountry": "Ireland"}]}}, "ReferencesModule": {"ReferenceList": {"Reference": [{"ReferencePMID": "32573764", "ReferenceType": "derived", "ReferenceCitation": "Schwartz SG, Wang X, Chavis P, Kuriyan AE, Abariga SA. Vitamin A and fish oils for preventing the progression of retinitis pigmentosa. Cochrane Database Syst Rev. 2020 Jun 18;6(6):CD008428. doi: 10.1002/14651858.CD008428.pub3."}]}}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000012173", "ConditionMeshTerm": "Retinitis"}, {"ConditionMeshId": "D000012174", "ConditionMeshTerm": "Retinitis Pigmentosa"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000012164", "ConditionAncestorTerm": "Retinal Diseases"}, {"ConditionAncestorId": "D000005128", "ConditionAncestorTerm": "Eye Diseases"}, {"ConditionAncestorId": "D000015785", "ConditionAncestorTerm": "Eye Diseases, Hereditary"}, {"ConditionAncestorId": "D000058499", "ConditionAncestorTerm": "Retinal Dystrophies"}, {"ConditionAncestorId": "D000012162", "ConditionAncestorTerm": "Retinal Degeneration"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M14160", "ConditionBrowseLeafName": "Retinitis", "ConditionBrowseLeafAsFound": "Retinitis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14161", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14151", "ConditionBrowseLeafName": "Retinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M7423", "ConditionBrowseLeafName": "Eye Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M17491", "ConditionBrowseLeafName": "Eye Diseases, Hereditary", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M28260", "ConditionBrowseLeafName": "Retinal Dystrophies", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M14149", "ConditionBrowseLeafName": "Retinal Degeneration", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T4945", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T591", "ConditionBrowseLeafName": "Autosomal Dominant Multiple Pterygium Syndrome", "ConditionBrowseLeafAsFound": "Autosomal Dominant", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC11", "ConditionBrowseBranchName": "Eye Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}, "InterventionBrowseModule": {"InterventionMeshList": {"InterventionMesh": [{"InterventionMeshId": "C000009166", "InterventionMeshTerm": "Retinol acetate"}]}, "InterventionAncestorList": {"InterventionAncestor": [{"InterventionAncestorId": "D000000276", "InterventionAncestorTerm": "Adjuvants, Immunologic"}, {"InterventionAncestorId": "D000007155", "InterventionAncestorTerm": "Immunologic Factors"}, {"InterventionAncestorId": "D000045505", "InterventionAncestorTerm": "Physiological Effects of Drugs"}, {"InterventionAncestorId": "D000016588", "InterventionAncestorTerm": "Anticarcinogenic Agents"}, {"InterventionAncestorId": "D000020011", "InterventionAncestorTerm": "Protective Agents"}, {"InterventionAncestorId": "D000000970", "InterventionAncestorTerm": "Antineoplastic Agents"}]}, "InterventionBrowseLeafList": {"InterventionBrowseLeaf": [{"InterventionBrowseLeafId": "M303191", "InterventionBrowseLeafName": "Retinol acetate", "InterventionBrowseLeafAsFound": "Q-tip", "InterventionBrowseLeafRelevance": "high"}, {"InterventionBrowseLeafId": "M20472", "InterventionBrowseLeafName": "Acetic Acid", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M16696", "InterventionBrowseLeafName": "Vitamin A", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M302471", "InterventionBrowseLeafName": "Retinol palmitate", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M2780", "InterventionBrowseLeafName": "Adjuvants, Immunologic", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M9353", "InterventionBrowseLeafName": "Immunologic Factors", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M21022", "InterventionBrowseLeafName": "Protective Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "T462", "InterventionBrowseLeafName": "Retinol", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "T436", "InterventionBrowseLeafName": "Acetic Acid", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "T468", "InterventionBrowseLeafName": "Vitamin A", "InterventionBrowseLeafRelevance": "low"}]}, "InterventionBrowseBranchList": {"InterventionBrowseBranch": [{"InterventionBrowseBranchAbbrev": "ANeo", "InterventionBrowseBranchName": "Antineoplastic Agents"}, {"InterventionBrowseBranchAbbrev": "All", "InterventionBrowseBranchName": "All Drugs and Chemicals"}, {"InterventionBrowseBranchAbbrev": "Infe", "InterventionBrowseBranchName": "Anti-Infective Agents"}, {"InterventionBrowseBranchAbbrev": "Micro", "InterventionBrowseBranchName": "Micronutrients"}, {"InterventionBrowseBranchAbbrev": "Vi", "InterventionBrowseBranchName": "Vitamins"}]}}}}}, {"Rank": 5, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT01160107", "OrgStudyIdInfo": {"OrgStudyId": "RV-MM-PI-302"}, "SecondaryIdInfoList": {"SecondaryIdInfo": [{"SecondaryId": "2007-007616-28", "SecondaryIdType": "EudraCT Number"}]}, "Organization": {"OrgFullName": "Fondazione EMN Italy Onlus", "OrgClass": "OTHER"}, "BriefTitle": "Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients", "OfficialTitle": "A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients", "Acronym": "RP_MPR"}, "StatusModule": {"StatusVerifiedDate": "March 2022", "OverallStatus": "Active, not recruiting", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "July 2008", "StartDateType": "Actual"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "August 2012", "PrimaryCompletionDateType": "Actual"}, "CompletionDateStruct": {"CompletionDate": "December 2023", "CompletionDateType": "Anticipated"}, "StudyFirstSubmitDate": "July 9, 2010", "StudyFirstSubmitQCDate": "July 9, 2010", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "July 12, 2010", "StudyFirstPostDateType": "Estimate"}, "LastUpdateSubmitDate": "March 24, 2022", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "March 25, 2022", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Fondazione EMN Italy Onlus", "LeadSponsorClass": "OTHER"}}, "OversightModule": {"OversightHasDMC": "Yes", "IsFDARegulatedDrug": "No", "IsFDARegulatedDevice": "No"}, "DescriptionModule": {"BriefSummary": "This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR (and CR) in newly diagnosed elderly MM patients.", "DetailedDescription": "This phase II study is a multicenter, open label trial designed to determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR (and CR) in newly diagnosed elderly MM patients.\n\nThis study consists of 3 phases for each study subject: Pre-treatment, Treatment, long-term follow-up (LTFU).\n\nPre-treatment period: after providing written informed consent, patients will undergo screening for protocol eligibility as outlined in the Schedule of Study Assessments.\n\nTreatment period: includes induction, consolidation and maintenance.\n\nInduction regimen:Patients will start induction treatment with association of Lenalidomide and Prednisone (RP).\n\nConsolidation regimen After the completion of the 4 RP cycles therapy will continue with the MPR association:\u00b7\n\nAccording to the results after the first stage the decisions are as follows: 1. The study may continue to a second stage, at the same dose of lenalidomide of MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%;\n\n2. The study may be stopped (if PR < 40% and grade 3-4 adverse events > 25-30%)\n\n3. A new first stage may be started:\n\nAt an increase dose of Lenalidomide administered in advanced MPR cycles if grade 3-4 adverse events are < 25-30%, independently from efficacy;\nAt a reduced dose of Lenalidomide administered in advanced MPR cycles if grade 3-4 adverse events are > 50% and PR rate > 50%\n\nMaintenance: Within 3 months from the last MPR cycle, therapy will continue with RP as maintenance.\n\nEach cycle will be repeated every 28 days, until PD."}, "ConditionsModule": {"ConditionList": {"Condition": ["Multiple Myeloma"]}, "KeywordList": {"Keyword": ["Diagnosis", "Elderly Patients", "Imids", "Chemotherapy"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 2"]}, "DesignInfo": {"DesignAllocation": "N/A", "DesignInterventionModel": "Single Group Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "46", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "RP followed MPR", "ArmGroupType": "Experimental", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: RP followed by MPR"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Drug", "InterventionName": "RP followed by MPR", "InterventionDescription": "Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%; 2. The study stop (if PR <40% and grade 3-4 adverse events >25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are < 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are > 50% and PR rate > 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["RP followed MPR"]}, "InterventionOtherNameList": {"InterventionOtherName": ["Revlimid", "Prednisone", "Melphalan"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "RP as induction followed by MPR as consolidation treatment is safe and induce a significant rate of PR (and CR)", "PrimaryOutcomeDescription": "Determine whether the association of RP as induction followed by MPR as consolidation treatment is safe and induce a significant rate of PR (and CR) in elderly patients with newly diagnosed multiple myeloma.", "PrimaryOutcomeTimeFrame": "Approximately 24 months"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Determine the progression free survival (PFS), overall survival (OS) and whether responses obtained with RP - MPR treatment, are associated with a prolongation of PFS, in comparison with non-responding patients.", "SecondaryOutcomeDescription": "The secondary objectives of this study are:\n\nTo determine progression free survival (PFS)\nTo determine overall survival (OS)\nTo determine whether responses obtained with RP - MPR treatment, are associated with a prolongation of PFS, in comparison with non-responding patients.", "SecondaryOutcomeTimeFrame": "Approximately 24 months"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nPatient is 65 years of age or older at the time of signing the informed consent.\nPatient is, in the investigator(s) opinion willing and able to comply with the protocol requirements.\nPatient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.\nMale patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) during study drug therapy (including dose interruption) and for 4 weeks after discontinuation of lenalidomide therapy.\nFemale patient is either post-menopausal for 24 consecutive months or surgically sterilised or agree to continuous abstinence from heterosexual sexual contact or willing to use two acceptable method of birth control at the same time (one highly effective method and one additional effective method)(Highly Effective Methods: Intrauterine device -IUD-; Hormonal -birth control pills, injections, implants-; tubal ligation; partner's vasectomy; Additional Effective Methods: Latex condom; Diaphragm; Cervical Cap) for 4 weeks prior to beginning study drug therapy, during study drug therapy (including dose interruption) and for 4 weeks after discontinuation of lenalidomide therapy.\nPatient was a newly diagnosed multiple myeloma based on standard criteria\nPatient has measurable disease, defined as follows: - Secretory myeloma: any quantifiable serum monoclonal protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain excretion of >200 mg/24 hours; - Non-secretory myeloma: > 30% plasma cells in the bone marrow and at least one plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e., MRI or CT scan).\nPatient has a Karnofsky performance status \u2265 50%.\nPatient has a life-expectancy >3 months.\n\nExclusion Criteria:\n\nAny serious medical condition, laboratory abnormality or psychiatric illness that prevented the subject from signing the informed consent form or placed the subjects at unacceptable risk.\nPrevious treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid; < to the equivalent of dexamethasone 40 mg/day for 4 days).\nPregnant or lactating females\nKnown positive for HIV or active infectious hepatitis type A, B or C", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "65 Years", "StdAgeList": {"StdAge": ["Older Adult"]}}, "ContactsLocationsModule": {"OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Mario Boccadoro, MD", "OverallOfficialAffiliation": "S.C. Ematologia U - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO", "OverallOfficialRole": "Principal Investigator"}]}}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000009101", "ConditionMeshTerm": "Multiple Myeloma"}, {"ConditionMeshId": "D000054219", "ConditionMeshTerm": "Neoplasms, Plasma Cell"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000009370", "ConditionAncestorTerm": "Neoplasms by Histologic Type"}, {"ConditionAncestorId": "D000009369", "ConditionAncestorTerm": "Neoplasms"}, {"ConditionAncestorId": "D000020141", "ConditionAncestorTerm": "Hemostatic Disorders"}, {"ConditionAncestorId": "D000014652", "ConditionAncestorTerm": "Vascular Diseases"}, {"ConditionAncestorId": "D000002318", "ConditionAncestorTerm": "Cardiovascular Diseases"}, {"ConditionAncestorId": "D000010265", "ConditionAncestorTerm": "Paraproteinemias"}, {"ConditionAncestorId": "D000001796", "ConditionAncestorTerm": "Blood Protein Disorders"}, {"ConditionAncestorId": "D000006402", "ConditionAncestorTerm": "Hematologic Diseases"}, {"ConditionAncestorId": "D000006474", "ConditionAncestorTerm": "Hemorrhagic Disorders"}, {"ConditionAncestorId": "D000008232", "ConditionAncestorTerm": "Lymphoproliferative Disorders"}, {"ConditionAncestorId": "D000007160", "ConditionAncestorTerm": "Immunoproliferative Disorders"}, {"ConditionAncestorId": "D000007154", "ConditionAncestorTerm": "Immune System Diseases"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M11210", "ConditionBrowseLeafName": "Multiple Myeloma", "ConditionBrowseLeafAsFound": "Multiple Myeloma", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M26741", "ConditionBrowseLeafName": "Neoplasms, Plasma Cell", "ConditionBrowseLeafAsFound": "Multiple Myeloma", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M11467", "ConditionBrowseLeafName": "Neoplasms by Histologic Type", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M21130", "ConditionBrowseLeafName": "Hemostatic Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M4211", "ConditionBrowseLeafName": "Blood Coagulation Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M16552", "ConditionBrowseLeafName": "Vascular Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M12330", "ConditionBrowseLeafName": "Paraproteinemias", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M4229", "ConditionBrowseLeafName": "Blood Protein Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M8642", "ConditionBrowseLeafName": "Hematologic Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M8712", "ConditionBrowseLeafName": "Hemorrhagic Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M10377", "ConditionBrowseLeafName": "Lymphoproliferative Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M9358", "ConditionBrowseLeafName": "Immunoproliferative Disorders", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M9352", "ConditionBrowseLeafName": "Immune System Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T3947", "ConditionBrowseLeafName": "Multiple Myeloma", "ConditionBrowseLeafAsFound": "Multiple Myeloma", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC04", "ConditionBrowseBranchName": "Neoplasms"}, {"ConditionBrowseBranchAbbrev": "BC14", "ConditionBrowseBranchName": "Heart and Blood Diseases"}, {"ConditionBrowseBranchAbbrev": "BC15", "ConditionBrowseBranchName": "Blood and Lymph Conditions"}, {"ConditionBrowseBranchAbbrev": "BC20", "ConditionBrowseBranchName": "Immune System Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}, "InterventionBrowseModule": {"InterventionMeshList": {"InterventionMesh": [{"InterventionMeshId": "D000011241", "InterventionMeshTerm": "Prednisone"}, {"InterventionMeshId": "D000008558", "InterventionMeshTerm": "Melphalan"}]}, "InterventionAncestorList": {"InterventionAncestor": [{"InterventionAncestorId": "D000000893", "InterventionAncestorTerm": "Anti-Inflammatory Agents"}, {"InterventionAncestorId": "D000005938", "InterventionAncestorTerm": "Glucocorticoids"}, {"InterventionAncestorId": "D000006728", "InterventionAncestorTerm": "Hormones"}, {"InterventionAncestorId": "D000006730", "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"InterventionAncestorId": "D000045505", "InterventionAncestorTerm": "Physiological Effects of Drugs"}, {"InterventionAncestorId": "D000018931", "InterventionAncestorTerm": "Antineoplastic Agents, Hormonal"}, {"InterventionAncestorId": "D000000970", "InterventionAncestorTerm": "Antineoplastic Agents"}, {"InterventionAncestorId": "D000018906", "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"}, {"InterventionAncestorId": "D000000477", "InterventionAncestorTerm": "Alkylating Agents"}, {"InterventionAncestorId": "D000045504", "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"}, {"InterventionAncestorId": "D000019653", "InterventionAncestorTerm": "Myeloablative Agonists"}, {"InterventionAncestorId": "D000007166", "InterventionAncestorTerm": "Immunosuppressive Agents"}, {"InterventionAncestorId": "D000007155", "InterventionAncestorTerm": "Immunologic Factors"}]}, "InterventionBrowseLeafList": {"InterventionBrowseLeaf": [{"InterventionBrowseLeafId": "M13273", "InterventionBrowseLeafName": "Prednisone", "InterventionBrowseLeafAsFound": "Second", "InterventionBrowseLeafRelevance": "high"}, {"InterventionBrowseLeafId": "M1725", "InterventionBrowseLeafName": "Lenalidomide", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M10693", "InterventionBrowseLeafName": "Melphalan", "InterventionBrowseLeafAsFound": "Collected", "InterventionBrowseLeafRelevance": "high"}, {"InterventionBrowseLeafId": "M3369", "InterventionBrowseLeafName": "Anti-Inflammatory Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M8199", "InterventionBrowseLeafName": "Glucocorticoids", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M8941", "InterventionBrowseLeafName": "Hormones", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M8940", "InterventionBrowseLeafName": "Hormone Antagonists", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M20119", "InterventionBrowseLeafName": "Antineoplastic Agents, Hormonal", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M20095", "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M2972", "InterventionBrowseLeafName": "Alkylating Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M9364", "InterventionBrowseLeafName": "Immunosuppressive Agents", "InterventionBrowseLeafRelevance": "low"}, {"InterventionBrowseLeafId": "M9353", "InterventionBrowseLeafName": "Immunologic Factors", "InterventionBrowseLeafRelevance": "low"}]}, "InterventionBrowseBranchList": {"InterventionBrowseBranch": [{"InterventionBrowseBranchAbbrev": "Infl", "InterventionBrowseBranchName": "Anti-Inflammatory Agents"}, {"InterventionBrowseBranchAbbrev": "ANeo", "InterventionBrowseBranchName": "Antineoplastic Agents"}, {"InterventionBrowseBranchAbbrev": "All", "InterventionBrowseBranchName": "All Drugs and Chemicals"}]}}}}}, {"Rank": 6, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT03563846", "OrgStudyIdInfo": {"OrgStudyId": "G28-005"}, "Organization": {"OrgFullName": "Ritter Pharmaceuticals, Inc.", "OrgClass": "INDUSTRY"}, "BriefTitle": "Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects", "OfficialTitle": "Prospective, Open-Label, Randomized, Two-Period, Two-Sequence, Crossover Study Comparing RP-G28 Administered in the Fasted State and the Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Volunteers", "Acronym": "RP"}, "StatusModule": {"StatusVerifiedDate": "June 2018", "OverallStatus": "Completed", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "March 9, 2018", "StartDateType": "Actual"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "April 13, 2018", "PrimaryCompletionDateType": "Actual"}, "CompletionDateStruct": {"CompletionDate": "April 13, 2018", "CompletionDateType": "Actual"}, "StudyFirstSubmitDate": "April 2, 2018", "StudyFirstSubmitQCDate": "June 19, 2018", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "June 20, 2018", "StudyFirstPostDateType": "Actual"}, "LastUpdateSubmitDate": "August 6, 2018", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "August 8, 2018", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Ritter Pharmaceuticals, Inc.", "LeadSponsorClass": "INDUSTRY"}}, "OversightModule": {"IsFDARegulatedDrug": "Yes", "IsFDARegulatedDevice": "No"}, "DescriptionModule": {"BriefSummary": "Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.", "DetailedDescription": "This randomized, open-label, 2-period, 2-sequence, crossover study is designed to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28, which is being developed for the treatment of lactose intolerance. The study consists of a screening visit (during the interval from Day -21 to Day -3), baseline/check-in to the clinical research unit (Day -2 to Day -1), 2 treatment periods (Day 1 and Day 3), a 48-hour washout between doses, check-out from the clinical research unit (Day 4), and 1 follow-up phone call conducted 7 to 10 days after the final dose of the study drug (i.e., during the interval from Day 10 to Day 13). The duration of subject study participation is approximately 5 weeks. Plasma samples for PK analysis will be taken at specified timepoints from 24 hours prior to each dose through 24 hours after each dose."}, "ConditionsModule": {"ConditionList": {"Condition": ["Lactose Intolerance"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 1"]}, "DesignInfo": {"DesignAllocation": "Randomized", "DesignInterventionModel": "Crossover Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "14", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "RP-G28 administered in the fasted state", "ArmGroupType": "Experimental", "ArmGroupDescription": "RP-G28, 15 g dissolved in water, administered in the fasted state", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: RP-G28"]}}, {"ArmGroupLabel": "RP-G28 administered in the fed state", "ArmGroupType": "Experimental", "ArmGroupDescription": "RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: RP-G28"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Drug", "InterventionName": "RP-G28", "InterventionDescription": "RP-G28 is a purified galacto-oligosaccharide (GOS) product", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["RP-G28 administered in the fasted state", "RP-G28 administered in the fed state"]}, "InterventionOtherNameList": {"InterventionOtherName": ["galactic-oligosaccharide"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Area under the plasma concentration-time curve from time 0 extrapolated to infinity", "PrimaryOutcomeDescription": "Assess systemic exposure of RP-G28 when administered in the fed and fasted state", "PrimaryOutcomeTimeFrame": "Days 2 and 1 pretreatment; Day 1 post-treatment, Day 1-3 washout, Day 3 and 4 post-treatment"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Adverse events", "SecondaryOutcomeDescription": "Adverse events will be continuously monitored throughout the entire study, including follow-up.", "SecondaryOutcomeTimeFrame": "2, 3, 2 and 1 days pretreatment; 1 - 13 days post-treatment"}, {"SecondaryOutcomeMeasure": "Serum chemistry", "SecondaryOutcomeDescription": "Albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, carbon dioxide, creatinine, total bilirubin, gamma glutamyl transferase, glucose, lactic dehydrogenase (lactate dehydrogenase), phosphorus, potassium, sodium, total cholesterol, total protein, uric acid, and vitamin D.", "SecondaryOutcomeTimeFrame": "21 and 3 days pretreatment; day 4 post-treatment"}, {"SecondaryOutcomeMeasure": "Hematology", "SecondaryOutcomeDescription": "Number of subjects with abnormal laboratory values will be flagged and summarized separately", "SecondaryOutcomeTimeFrame": "21 and 3 days pretreatment; day 4 post-treatment"}, {"SecondaryOutcomeMeasure": "Urinalysis", "SecondaryOutcomeDescription": "Number of subjects with abnormal laboratory values will be flagged and summarized separately", "SecondaryOutcomeTimeFrame": "2, 3, 2 and 1 days pretreatment; day 1 and 3 post-treatment"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nHealthy male and female subjects between 18 and 60 years of age\nSubjects with body weights greater than or equal to 50 kg and a body mass index (BMI) between 18 kg/m2 and 32 kg/m2\nFemale subjects of childbearing potential and males and their female partner(s) of childbearing potential must agree to use 2 forms of contraception, 1 of which must be a barrier method, during the study and for 30 days after the end of the study\n\nExclusion Criteria:\n\nPregnant or lactating females or male partners of females who are pregnant or lactating.\nSubjects with any history of clinically significant bronchopulmonary, cardiovascular, cerebrovascular, hematologic, renal, hepatic, neurological, psychiatric, metabolic, or endocrine (eg, diabetes or thyroid disease) disease/disorder.\nUse of prescription or over-the-counter (OTC) drugs, including vitamins and herbal or dietary supplements within 2 weeks (4 weeks for enzyme inducers including St. John's Wort) or 5 half-lives (whichever is longer), prior to the baseline/check-in visit, unless in the opinion of the investigator, prior use of the medication will not interfere with the study procedures or compromise subject safety.\nSubjects with sustained supine or semi-supine systolic blood pressure of < 90 or > 140 mm Hg and supine or semi-supine diastolic blood pressure of < 50 or > 90 mm Hg at the screening or baseline/check-in visits.\nSubjects with a resting heart rate of < 45 or > 100 beats per minute at the screening or baseline/check in visits.\nSubjects with any clinically relevant deviation from normal during the physical examination, including vital signs at the screening or baseline/check-in visits.\nSubjects with a known history of hypercalcemia, hyperparathyroidism, or hypervitaminosis D.\nUse of calcium or vitamin D supplements (prescription or OTC) within 2 weeks prior to the baseline/check-in visit.\nSubjects with a history of allergic reactions or hypersensitivities to galacto-oligosaccharides or any significant drug-related or food-related allergy (such as anaphylaxis or hepatotoxicity).\nRegular use of probiotics, antacids, histamine type 2 (H2)-receptor blockers, proton pump inhibitors, or any medications that may alter the normal gastric environment and/or motility, or use of such medications within 2 weeks prior to the baseline/check-in visit.", "HealthyVolunteers": "Accepts Healthy Volunteers", "Gender": "All", "MinimumAge": "18 Years", "MaximumAge": "60 Years", "StdAgeList": {"StdAge": ["Adult"]}}, "ContactsLocationsModule": {"OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Paul G Pearson, PhD", "OverallOfficialAffiliation": "Ritter Pharmaceuticals", "OverallOfficialRole": "Study Director"}]}, "LocationList": {"Location": [{"LocationFacility": "Syneos Health", "LocationCity": "Miami", "LocationState": "Florida", "LocationZip": "33136", "LocationCountry": "United States"}]}}, "IPDSharingStatementModule": {"IPDSharing": "No"}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000007787", "ConditionMeshTerm": "Lactose Intolerance"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000008286", "ConditionAncestorTerm": "Malabsorption Syndromes"}, {"ConditionAncestorId": "D000007410", "ConditionAncestorTerm": "Intestinal Diseases"}, {"ConditionAncestorId": "D000005767", "ConditionAncestorTerm": "Gastrointestinal Diseases"}, {"ConditionAncestorId": "D000004066", "ConditionAncestorTerm": "Digestive System Diseases"}, {"ConditionAncestorId": "D000002239", "ConditionAncestorTerm": "Carbohydrate Metabolism, Inborn Errors"}, {"ConditionAncestorId": "D000008661", "ConditionAncestorTerm": "Metabolism, Inborn Errors"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}, {"ConditionAncestorId": "D000008659", "ConditionAncestorTerm": "Metabolic Diseases"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M9957", "ConditionBrowseLeafName": "Lactose Intolerance", "ConditionBrowseLeafAsFound": "Lactose Intolerance", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M15507", "ConditionBrowseLeafName": "Syndrome", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M10430", "ConditionBrowseLeafName": "Malabsorption Syndromes", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M9596", "ConditionBrowseLeafName": "Intestinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M8035", "ConditionBrowseLeafName": "Gastrointestinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M6407", "ConditionBrowseLeafName": "Digestive System Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M10793", "ConditionBrowseLeafName": "Metabolism, Inborn Errors", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M4650", "ConditionBrowseLeafName": "Carbohydrate Metabolism, Inborn Errors", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M10791", "ConditionBrowseLeafName": "Metabolic Diseases", "ConditionBrowseLeafRelevance": "low"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC06", "ConditionBrowseBranchName": "Digestive System Diseases"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "BC18", "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC23", "ConditionBrowseBranchName": "Symptoms and General Pathology"}]}}}}}, {"Rank": 7, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT02860520", "OrgStudyIdInfo": {"OrgStudyId": "5724"}, "Organization": {"OrgFullName": "University Hospital, Strasbourg, France", "OrgClass": "OTHER"}, "BriefTitle": "Clinical Implication of Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing.", "OfficialTitle": "Clinical Implication of the Molecular Diagnostic Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing (RP-SEQ-HD)", "Acronym": "RP-SEQ-HD"}, "StatusModule": {"StatusVerifiedDate": "April 2022", "OverallStatus": "Recruiting", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "November 3, 2015", "StartDateType": "Actual"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "August 2025", "PrimaryCompletionDateType": "Anticipated"}, "CompletionDateStruct": {"CompletionDate": "August 2025", "CompletionDateType": "Anticipated"}, "StudyFirstSubmitDate": "August 1, 2016", "StudyFirstSubmitQCDate": "August 4, 2016", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "August 9, 2016", "StudyFirstPostDateType": "Estimate"}, "LastUpdateSubmitDate": "April 19, 2022", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "April 20, 2022", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "University Hospital, Strasbourg, France", "LeadSponsorClass": "OTHER"}}, "OversightModule": {"OversightHasDMC": "No"}, "DescriptionModule": {"BriefSummary": "The retinitis pigmentosa (RP) are genetic conditions that cause retinal degeneration leading to severe low vision and is the leading cause of consultation in reference centers dedicated to the ophthalmic genetics. These rare diseases are characterized by a triple heterogeneity (clinical, genetic and molecular), which made them unreachable by traditional molecular diagnostic sequencing technology by the large number of genes to be tested (> 190).\n\nThe advent of high-throughput sequencing (NGS) and targeted capture has opened unexpected possibilities of investigation and ultimately to improve the care of patients. This project aims to study the genetic and molecular epidemiology of an interregional french (grand EST) cohort of patients. Patients receive a detailed retinal phenotype (visual acuity, visual field, photographs of the fundus and ERG). Their DNA will be analyzed by NGS targets the 190 known genes (https://sph.uth.edu/retnet/).\n\nThis research will provide a molecular epidemiological cohort study compared to prior publications on the frequency of genes involved. The benefit for patients is important to: establish a mode of transmission of the disease and optimize genetic counseling (currently very empirical); establish phenotype-genotype correlations in the French population (very few studies to date) and from the data of international literature; identify patients likely to be included in future therapeutic protocols of research; identify patients with significant potential for future projects to identify new genes.\n\nThe primary purpose of the protocol is to use high throughput sequencing to identify pathogenic variants in genes involved in RP.\n\nThe secondary purposes will be the following:\n\nDetermining the diagnostic yield\nStudy the genotype-phenotype correlation.\n\nThe secondary purposes will be the following:\n\nDetermining the diagnostic yield\nStudy the genotype-phenotype correlation"}, "ConditionsModule": {"ConditionList": {"Condition": ["Retinitis Pigmentosa"]}, "KeywordList": {"Keyword": ["Retinitis pigmentosa:"]}}, "DesignModule": {"StudyType": "Observational", "PatientRegistry": "No", "DesignInfo": {"DesignObservationalModelList": {"DesignObservationalModel": ["Cohort"]}, "DesignTimePerspectiveList": {"DesignTimePerspective": ["Prospective"]}}, "BioSpec": {"BioSpecRetention": "Samples With DNA", "BioSpecDescription": "Whole blood"}, "EnrollmentInfo": {"EnrollmentCount": "500", "EnrollmentType": "Anticipated"}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Number of patients with a deleterious mutation", "PrimaryOutcomeTimeFrame": "18 months"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Percentage of positive diagnostic", "SecondaryOutcomeTimeFrame": "18 months"}, {"SecondaryOutcomeMeasure": "Number of gene with a genotype-phenotype correlation", "SecondaryOutcomeTimeFrame": "18 months"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nSubject of both sex, aged at least 2 years, being diagnosed with an RP, and/or having a family history of RP\nInformed about the results of the preliminary medical visit, or which (s) holder (s) parental authority or the guardian / curator has (have) was (been) informed\nInformed consent signed\nAffiliation to the French health system\n\nExclusion Criteria:\n\nThe patient does not want to participate to the protocol\nIntercurrent diseases do not allow the practice of tests provided for this protocol\nPhenocopy\nSubject excluded or being excluded by another protocol\nSubject in emergency case\nSubject under judicial protection", "HealthyVolunteers": "Accepts Healthy Volunteers", "Gender": "All", "MinimumAge": "2 Years", "StdAgeList": {"StdAge": ["Child", "Adult", "Older Adult"]}, "StudyPopulation": "Patients with an RP and/or having a family history of RP", "SamplingMethod": "Non-Probability Sample"}, "ContactsLocationsModule": {"CentralContactList": {"CentralContact": [{"CentralContactName": "H\u00e9l\u00e8ne DOLLFUS, MD", "CentralContactRole": "Contact", "CentralContactPhone": "33.3.88.12.81.19", "CentralContactEMail": "helene.dollfus@chru-strasbourg.fr"}, {"CentralContactName": "Jean MULLER, PHD", "CentralContactRole": "Contact", "CentralContactPhone": "33.3.69.55.11.66", "CentralContactEMail": "jean.muller@chru-strasbourg.fr"}]}, "OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "H\u00e9l\u00e8ne DOLLFUS, MD", "OverallOfficialAffiliation": "H\u00f4pitaux Universitaires de Strasbourg", "OverallOfficialRole": "Principal Investigator"}]}, "LocationList": {"Location": [{"LocationFacility": "Service d'Ophtalmologie CHU H\u00f4pital G\u00e9n\u00e9ral", "LocationStatus": "Not yet recruiting", "LocationCity": "Dijon", "LocationZip": "21000", "LocationCountry": "France", "LocationContactList": {"LocationContact": [{"LocationContactName": "Catherine CREUZOT-GARCHER, MD", "LocationContactRole": "Contact", "LocationContactPhone": "33.3.80.29.37.56", "LocationContactEMail": "catherine.creuzot-garcher@chu-dijon.fr"}, {"LocationContactName": "Catherine CREUZOT-GARCHER, MD", "LocationContactRole": "Principal Investigator"}, {"LocationContactName": "Alain BRON, MD", "LocationContactRole": "Sub-Investigator"}]}}, {"LocationFacility": "Service d'Ophtalmologie, H\u00f4pital Robert Debr\u00e9, CHR", "LocationStatus": "Not yet recruiting", "LocationCity": "Reims", "LocationZip": "51092", "LocationCountry": "France", "LocationContactList": {"LocationContact": [{"LocationContactName": "Carl ARNDT, MD", "LocationContactRole": "Contact", "LocationContactPhone": "33.3.26.78.77.20", "LocationContactEMail": "prarndt@gmail.com"}, {"LocationContactName": "Carl ARNDT, MD", "LocationContactRole": "Principal Investigator"}, {"LocationContactName": "Dominique GAILLARD, MD", "LocationContactRole": "Sub-Investigator"}]}}, {"LocationFacility": "Affections Rares en G\u00e9n\u00e9tique Ophtalmologique (CARGO) H\u00f4pital Civil, H\u00f4pitaux Universitaires de Strasbourg", "LocationStatus": "Recruiting", "LocationCity": "Strasbourg", "LocationZip": "67091", "LocationCountry": "France", "LocationContactList": {"LocationContact": [{"LocationContactName": "H\u00e9l\u00e8ne DOLLFUS, MD", "LocationContactRole": "Contact", "LocationContactPhone": "33.3.88.11.67.53", "LocationContactEMail": "helene.dollfus@chru-strasbourg.fr"}, {"LocationContactName": "Jean MULLER, PHD", "LocationContactRole": "Contact", "LocationContactPhone": "03.69.55.11.66", "LocationContactEMail": "jean.muller@chru-strasbourg.fr"}, {"LocationContactName": "H\u00e9l\u00e8ne DOLLFUS, MD", "LocationContactRole": "Principal Investigator"}, {"LocationContactName": "Yaumara PERDOMO, MD", "LocationContactRole": "Sub-Investigator"}]}}, {"LocationFacility": "Service d'Ophtalmologie, CHU BRABOIS", "LocationStatus": "Not yet recruiting", "LocationCity": "Vandoeuvre Les Nancy", "LocationZip": "54500", "LocationCountry": "France", "LocationContactList": {"LocationContact": [{"LocationContactName": "Karine ANGIOI-DUPREZ, MD", "LocationContactRole": "Contact", "LocationContactPhone": "33.3.15.30.39", "LocationContactEMail": "k.angioi-duprez@chu-nancy.fr"}, {"LocationContactName": "Karine ANGIOI-DUPREZ, MD", "LocationContactRole": "Principal Investigator"}, {"LocationContactName": "Bruno LEHEUP, MD", "LocationContactRole": "Sub-Investigator"}, {"LocationContactName": "Philippe JONVEAUX, MD", "LocationContactRole": "Sub-Investigator"}]}}]}}, "IPDSharingStatementModule": {"IPDSharing": "No"}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000012173", "ConditionMeshTerm": "Retinitis"}, {"ConditionMeshId": "D000012174", "ConditionMeshTerm": "Retinitis Pigmentosa"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000012164", "ConditionAncestorTerm": "Retinal Diseases"}, {"ConditionAncestorId": "D000005128", "ConditionAncestorTerm": "Eye Diseases"}, {"ConditionAncestorId": "D000015785", "ConditionAncestorTerm": "Eye Diseases, Hereditary"}, {"ConditionAncestorId": "D000058499", "ConditionAncestorTerm": "Retinal Dystrophies"}, {"ConditionAncestorId": "D000012162", "ConditionAncestorTerm": "Retinal Degeneration"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M14160", "ConditionBrowseLeafName": "Retinitis", "ConditionBrowseLeafAsFound": "Retinitis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14161", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14151", "ConditionBrowseLeafName": "Retinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M7423", "ConditionBrowseLeafName": "Eye Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M17491", "ConditionBrowseLeafName": "Eye Diseases, Hereditary", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M28260", "ConditionBrowseLeafName": "Retinal Dystrophies", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M14149", "ConditionBrowseLeafName": "Retinal Degeneration", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T4945", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC11", "ConditionBrowseBranchName": "Eye Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}}}}, {"Rank": 8, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT02548572", "OrgStudyIdInfo": {"OrgStudyId": "IMC1TES/RP"}, "Organization": {"OrgFullName": "Wills Eye", "OrgClass": "OTHER"}, "BriefTitle": "Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study", "OfficialTitle": "Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy NSR Device Study - A Multicenter Study", "Acronym": "TES/RP"}, "StatusModule": {"StatusVerifiedDate": "April 2019", "OverallStatus": "Withdrawn", "WhyStopped": "Could not recruit patients", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "January 2019", "StartDateType": "Anticipated"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "December 2020", "PrimaryCompletionDateType": "Anticipated"}, "CompletionDateStruct": {"CompletionDate": "December 2020", "CompletionDateType": "Anticipated"}, "StudyFirstSubmitDate": "September 9, 2015", "StudyFirstSubmitQCDate": "September 11, 2015", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "September 14, 2015", "StudyFirstPostDateType": "Estimate"}, "LastUpdateSubmitDate": "April 29, 2019", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "May 1, 2019", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Wills Eye", "LeadSponsorClass": "OTHER"}, "CollaboratorList": {"Collaborator": [{"CollaboratorName": "Okuvision GmbH", "CollaboratorClass": "INDUSTRY"}]}}, "OversightModule": {"OversightHasDMC": "Yes", "IsFDARegulatedDrug": "No", "IsFDARegulatedDevice": "Yes"}, "DescriptionModule": {"BriefSummary": "Several studies have shown that TES in RP patients may help to slow the progressive deterioration of this degenerative disease. The end point of this clinical trial is to slow or stop disease progression with weekly treatment using TES for 1 year.", "DetailedDescription": "The following proposed study (ICM1TES/RP) will investigate the therapeutic aspects of transcorneal electrical stimulation (TES) on the eye in patients with retinitis pigmentosa (RP). It will utilize the Okuvision TES system, a Wills Eye Hospital-sponsored FDA non-significant risk (NSR) medical device, OkuStim\u00ae (CE-marked OkuStim\u00ae) for the application of electrical stimulation directly to the eye via a corneal contact electrode.\n\nStudy Design - Multi-center, prospective, randomized sham controlled 1:1 Clinical trial.\n\nStudy treatments - Patients will be randomized in a 1:1 ratio. Patients in treatment group will have TES at 200% of phosphene threshold for 30 minutes once weekly for 52 weeks in both eyes. Patients in sham group will also wear electrodes on both eyes, but no energy is turned on and both eyes are sham.\n\nDuration of study - anticipated duration is 36 months, 12 months for recruitment, 12 months for treatment and sham groups and followed for 18 months, plus 6 months for analysis.\n\nInclusion Criteria - Diagnosis of RP, 22-80 years of age, no other ocular disease, able to complete all visits.\n\nTreatments - TES, 30 minute treatment weekly for 52 weeks at 0.8mA\n\nNumber of patients - 90 patients in treatment arm and 90 patients in sham arm. Electrodes will be placed on both eyes, both eyes will be treated in treatment group and in the sham group both eyes will be considered. However due to the possibility of drop out using 15% we will recruit 210 patients (15 patients per center).\n\nScreening -\n\nVA & Phosphene threshold evaluation\nVfiii4e, vfVe, Octopus 900, complete eye exam, fundus photo, OCT and Contrast sensitivity, electro-physiology.\nEligibility requirements met, then schedule baseline.\n\nTests - Base Line: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, fundus photo, OCT, Contrast sensitivity, NEI VFQ-25, Photopic B-wave ERG, blood draw for genetic test (unless genetic profile has been done).\n\n3 Month visit: VA, eye exam, Phosphene threshold, OCT & Photopic B-wave.\n\n6 Month visit: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, OCT & Contrast sensitivity, phosphine threshold & Photopic B-wave.\n\n9 Month visit: VA, eye exam, Phosphene threshold, OCT & Photopic B-wave.\n\n12 Month visit: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, OCT & Contrast sensitivity, NEI VFQ-25, phosphene threshold & Photopic B-wave\n\n18 Month visit: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, OCT & Contrast sensitivity, NEI VFQ-25 & phosphene threshold & Photopic B-wave."}, "ConditionsModule": {"ConditionList": {"Condition": ["Retinitis Pigmentosa"]}, "KeywordList": {"Keyword": ["Transcorneal Electrical Stimulation", "TES", "Retinitis Pigmentosa", "RP"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Not Applicable"]}, "DesignInfo": {"DesignAllocation": "Randomized", "DesignInterventionModel": "Parallel Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "Triple", "DesignWhoMaskedList": {"DesignWhoMasked": ["Participant", "Care Provider", "Investigator"]}}}, "EnrollmentInfo": {"EnrollmentCount": "0", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "Treatment group", "ArmGroupType": "Experimental", "ArmGroupDescription": "Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Device: Transcorneal Electrical Stimulation using Okustim device"]}}, {"ArmGroupLabel": "Sham group", "ArmGroupType": "Placebo Comparator", "ArmGroupDescription": "Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Device: Transcorneal Electrical Stimulation using Okustim device"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Device", "InterventionName": "Transcorneal Electrical Stimulation using Okustim device", "InterventionDescription": "The Okustim\u00ae stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim\u00ae device using the \"OkuEl\u00ae\" electrodes, which are held in place via the \"OkuSpex\u00ae\" frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Sham group", "Treatment group"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Octopus vfiii4e (Progressive slowing of Visual Field deterioration)", "PrimaryOutcomeDescription": "Octopus vfiii4e test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76 to analyze progressive slowing of Visual Field deterioration", "PrimaryOutcomeTimeFrame": "76 weeks"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Visual acuity (VA)", "SecondaryOutcomeDescription": "VA testing will be done at all visits", "SecondaryOutcomeTimeFrame": "76 weeks"}, {"SecondaryOutcomeMeasure": "Contrast sensitivity", "SecondaryOutcomeDescription": "Contrast sensitivity testing will be done at Baseline visit, Week 26, Week 53 and Week 76", "SecondaryOutcomeTimeFrame": "76 weeks"}, {"SecondaryOutcomeMeasure": "NEI-VFQ-25 total score & subscores", "SecondaryOutcomeDescription": "NEI-VFQ-25 survey will be filled out at Baseline visit and at Week 53", "SecondaryOutcomeTimeFrame": "53 weeks"}, {"SecondaryOutcomeMeasure": "Photopic b-wave ERG", "SecondaryOutcomeDescription": "Photopic b-wave ERG test will be done at Baseline visit, Week 13, Week 26, Week 39, Week 53 and Week 76", "SecondaryOutcomeTimeFrame": "76 weeks"}]}, "OtherOutcomeList": {"OtherOutcome": [{"OtherOutcomeMeasure": "Change in phosphene threshold detection levels", "OtherOutcomeDescription": "Change in phosphene threshold detection levels will be done at Screening visit, Baseline visit, Week 13, Week 26, Week 39, Week 53 and Week 76. This is an exploratory efficacy endpoint.", "OtherOutcomeTimeFrame": "76 weeks"}, {"OtherOutcomeMeasure": "Octopus GATE (static)", "OtherOutcomeDescription": "Octopus GATE (static) test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76. This is an exploratory efficacy endpoint.", "OtherOutcomeTimeFrame": "76 weeks"}, {"OtherOutcomeMeasure": "Octopus vf V4e (kinetic)", "OtherOutcomeDescription": "Octopus vf V4e (kinetic) test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76. This is an exploratory efficacy endpoint.", "OtherOutcomeTimeFrame": "76 weeks"}, {"OtherOutcomeMeasure": "SD-OCT (ez analysis)", "OtherOutcomeDescription": "SD-OCT (ez analysis) test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76. This is an exploratory efficacy endpoint.", "OtherOutcomeTimeFrame": "76 weeks"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nPatients with Retinitis Pigmentosa.\nAdult patients, 22-80 years of age, having provided written informed consent and HIPAA authorization.\nLogMAR VA 1.00 or better in both eyes.\nOctopus 900 Central Visual Field \u226510 degrees diameter around central fixation using stimulus sizes III4e and V4e in both eyes on kinetic testing.\nAgree to discontinue Vitamin A use and no intake for at least 2 months prior to baseline visit.\n\nExclusion Criteria:\n\nVisual field loss as demonstrated by Octopus 900 kinetic perimetry as <10 deg of remaining central visual field using stimulus sizes III4e and V4e.\nDue to distance or other reason, patients unable to travel to Philadelphia or respective centers for the treatment procedures and follow-up examinations.\nDiabetic retinopathy\nOcular neovascularisation of any origin\nAfter arterial or venous occlusion\nAfter retinal detachment or any vitreoretinal surgery with or without implantation.\nSilicone oil tamponade\nDry or exudative age-related macular degeneration\nMacular edema involving the foveal center as determined by SD-OCT\nAll forms of glaucoma\nAny form of corneal degeneration that reduces visual acuity\nSystemic diseases that are difficult to control or manage, which could hinder regular attendance at follow-up examinations\nPatients in a permanently poor general condition, which could hinder regular attendance at follow-up examinations\nPatients in whom phosphenes are only inducible at greater than, but not including, 0.8 mA.\nForms of mental illness related to the bipolar affective and schizoid-affective disorders, epilepsy, and all forms of dementia\nSimultaneous participation in another interventional study or history of interventions whose effect may still persist\nCurrent pregnancy, or being a woman with childbearing potential who is unwilling to use medically acceptable means of birth control for the study duration, or a woman unwilling to perform a pregnancy test at study entry\nAny patient can be excluded from the study as determined by the Principal Investigator.", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "22 Years", "MaximumAge": "80 Years", "StdAgeList": {"StdAge": ["Adult", "Older Adult"]}}, "ContactsLocationsModule": {"OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Leslie Hyman, PhD", "OverallOfficialAffiliation": "Wills Eye Hospital", "OverallOfficialRole": "Study Director"}]}, "LocationList": {"Location": [{"LocationFacility": "Wills Eye Health System", "LocationCity": "Philadelphia", "LocationState": "Pennsylvania", "LocationZip": "19107", "LocationCountry": "United States"}]}}, "IPDSharingStatementModule": {"IPDSharing": "Yes"}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000012173", "ConditionMeshTerm": "Retinitis"}, {"ConditionMeshId": "D000012174", "ConditionMeshTerm": "Retinitis Pigmentosa"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000012164", "ConditionAncestorTerm": "Retinal Diseases"}, {"ConditionAncestorId": "D000005128", "ConditionAncestorTerm": "Eye Diseases"}, {"ConditionAncestorId": "D000015785", "ConditionAncestorTerm": "Eye Diseases, Hereditary"}, {"ConditionAncestorId": "D000058499", "ConditionAncestorTerm": "Retinal Dystrophies"}, {"ConditionAncestorId": "D000012162", "ConditionAncestorTerm": "Retinal Degeneration"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M14160", "ConditionBrowseLeafName": "Retinitis", "ConditionBrowseLeafAsFound": "Retinitis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14161", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14151", "ConditionBrowseLeafName": "Retinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M7423", "ConditionBrowseLeafName": "Eye Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M17491", "ConditionBrowseLeafName": "Eye Diseases, Hereditary", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M28260", "ConditionBrowseLeafName": "Retinal Dystrophies", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M14149", "ConditionBrowseLeafName": "Retinal Degeneration", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T4945", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC11", "ConditionBrowseBranchName": "Eye Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}}}}, {"Rank": 9, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT01744782", "OrgStudyIdInfo": {"OrgStudyId": "RP103-08"}, "Organization": {"OrgFullName": "Horizon Pharma USA, Inc.", "OrgClass": "INDUSTRY"}, "BriefTitle": "Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis", "OfficialTitle": "An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Na\u00efve Patients With Cystinosis"}, "StatusModule": {"StatusVerifiedDate": "December 2017", "OverallStatus": "Completed", "StartDateStruct": {"StartDate": "December 20, 2012", "StartDateType": "Actual"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "December 13, 2016", "PrimaryCompletionDateType": "Actual"}, "CompletionDateStruct": {"CompletionDate": "December 13, 2016", "CompletionDateType": "Actual"}, "StudyFirstSubmitDate": "December 5, 2012", "StudyFirstSubmitQCDate": "December 5, 2012", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "December 7, 2012", "StudyFirstPostDateType": "Estimate"}, "ResultsFirstSubmitDate": "December 13, 2017", "ResultsFirstSubmitQCDate": "December 13, 2017", "ResultsFirstPostDateStruct": {"ResultsFirstPostDate": "January 16, 2018", "ResultsFirstPostDateType": "Actual"}, "LastUpdateSubmitDate": "January 17, 2018", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "February 14, 2018", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Horizon Pharma USA, Inc.", "LeadSponsorClass": "INDUSTRY"}}, "OversightModule": {"OversightHasDMC": "No", "IsFDARegulatedDrug": "Yes", "IsFDARegulatedDevice": "No"}, "DescriptionModule": {"BriefSummary": "This was a long-term, open-label study of the safety, tolerability and effectiveness of RP103 in cystinosis patients who were na\u00efve to any form of cysteamine treatment. Participants received RP103 treatment for at least 12 months. U.S. participants transitioned to the commercially approved drug PROCYSBI\u00ae. In Brazil, after at least 12 months of study participation and upon approval by the Brazilian regulatory authorities, participants were eligible to transition to a post-study drug supply program, and continue to receive the drug at no personal cost.", "DetailedDescription": "The purpose of this study was to gather information about the safety and effectiveness (how well it works to treat cystinosis) of a new drug called RP103.\n\nIn cystinosis, the body builds up cystine. When taken regularly, the active ingredient of an older, already approved drug called Cystagon\u00ae (cysteamine bitartrate) reduces cystine in the body. RP103 has the same active ingredient as Cystagon\u00ae and is designed to reduce cystine in a similar way that Cystagon\u00ae does. RP103 is also different from Cystagon\u00ae: Instead of the cysteamine bitartrate being absorbed from the stomach, RP103 is designed to be absorbed from the small intestine. This may make the effects of the drug last longer, so that it can be taken twice a day instead of four times a day like Cystagon\u00ae.\n\nTo decide if RP103 is effective, the study used two types of blood tests. One test is pharmacodynamics (PD), which measures the amount of white blood cell (WBC) cystine after taking study drug. WBC cystine is a laboratory test used to find out if cysteamine bitartrate is reducing cystine levels in the body. The second test is pharmacokinetics (PK), which measures the amount of cysteamine in the blood after taking the drug."}, "ConditionsModule": {"ConditionList": {"Condition": ["Cystinosis"]}, "KeywordList": {"Keyword": ["Nephropathic Cystinosis", "Cysteamine", "Delayed-release Cysteamine", "CTNS Protein, Human", "Orphan Disease"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 3"]}, "DesignInfo": {"DesignAllocation": "N/A", "DesignInterventionModel": "Single Group Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "None (Open Label)"}}, "EnrollmentInfo": {"EnrollmentCount": "17", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "RP103", "ArmGroupType": "Experimental", "ArmGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Drug: RP103"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Drug", "InterventionName": "RP103", "InterventionDescription": "Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m\u00b2/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was <1 nmol \u00bd cystine/mg protein.", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["RP103"]}, "InterventionOtherNameList": {"InterventionOtherName": ["Cysteamine Delayed-release Capsules"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Mean White Blood Cell (WBC) Cystine Concentration at Each Visit", "PrimaryOutcomeDescription": "Blood samples were taken 30 minutes after the morning RP103 dose at each study visit to determine White Blood Cell (WBC) cystine concentration. WBC cystine concentrations were determined using liquid chromatography.", "PrimaryOutcomeTimeFrame": "Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Month 6, Month 9, Month 12, Month 15, Month 18, Study Exit"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Number of Participants With Adverse Events", "SecondaryOutcomeDescription": "Safety was assessed by the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). An AE/adverse experience was any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. For additional information regarding adverse events, please see the safety section of the record.", "SecondaryOutcomeTimeFrame": "Day 1 through study exit"}, {"SecondaryOutcomeMeasure": "Maximum Observed Plasma Concentration (Cmax) of Cysteamine", "SecondaryOutcomeDescription": "Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. The maximum observed plasma concentration (Cmax) of cysteamine was determined directly from the data.", "SecondaryOutcomeTimeFrame": "30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later"}, {"SecondaryOutcomeMeasure": "Time of the Maximum Observed Plasma Concentration (Tmax) of Cysteamine", "SecondaryOutcomeDescription": "Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. The time of the maximum observed plasma concentration (Tmax) of cysteamine was determined directly from the data.", "SecondaryOutcomeTimeFrame": "30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later"}, {"SecondaryOutcomeMeasure": "Area Under the Plasma Concentration Versus Time Curve (AUC) of Cysteamine", "SecondaryOutcomeDescription": "Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. AUC values were estimated using non-compartmental analysis methods. AUClast was defined as the area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (720 minutes). AUCinf was defined as the area under the plasma concentration-versus-time curve from time 0 to infinity.", "SecondaryOutcomeTimeFrame": "30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nMale or female with a documented diagnosis of cystinosis\nNo clinically significant change in liver function tests, i.e. 1.5 times upper limit of normal (ULN) for alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and/or 1.5 times ULN for total bilirubin, within 6 months prior to Screening\nNo clinically significant change in renal function, i.e. estimated glomerular filtration rate (GFR) within 6 months prior to Screening\nMust have an estimated GFR > 20 mL/minute/1.73m\u00b2 (using the equation from Schwartz 2009 J Am Soc Nephrol 20:629-647)\nFemale participants who are sexually active and of childbearing potential, i.e. not surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception from Screening through completion of the study. Acceptable forms of contraception for this study include hormonal contraceptives (oral, implant, transdermal patch, or injection) at a stable dose for at least 3 months prior to Screening, barrier (spermicidal condom or diaphragm with spermicide), IUD, or a partner who has been vasectomized for at least 6 months. Childbearing potential was defined as a female who had reached menarche.\nParticipant or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study\nHad not taken any form of cysteamine bitartrate in the past\n\nExclusion Criteria:\n\nCurrent history of the following conditions or any other health issues that make it, in the opinion of the Investigator, unsafe for study participation:\nInflammatory bowel disease if currently active, or prior resection of the small intestine\nHeart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias, or poorly controlled hypertension) within 90 days prior to Screening\nActive bleeding disorder within 90 days prior to Screening\nHistory of malignant disease within 2 years prior to Screening\nHemoglobin level of < 10 g/dL at Screening or, in the opinion of the investigator, a hemoglobin level that would make it unsafe for study participation\nKnown hypersensitivity to penicillamine\nFemale subjects who were nursing, planning a pregnancy, or were known or suspected to be pregnant\nParticipants who, in the opinion of the investigator, were not able or willing to comply with study requirements\nHad received a kidney transplant or was currently on dialysis\nWas 6 years of age or older at the time of the Screening visit", "HealthyVolunteers": "No", "Gender": "All", "MaximumAge": "6 Years", "StdAgeList": {"StdAge": ["Child"]}}, "ContactsLocationsModule": {"OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Evelyn Olson, BS", "OverallOfficialAffiliation": "Horizon Pharma USA, Inc.", "OverallOfficialRole": "Study Director"}]}, "LocationList": {"Location": [{"LocationFacility": "Ann & Robert H. Lurie Children's Hospital of Chicago", "LocationCity": "Chicago", "LocationState": "Illinois", "LocationZip": "60611", "LocationCountry": "United States"}, {"LocationFacility": "Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de Sao Paulo", "LocationCity": "Sao Paulo", "LocationState": "SP", "LocationCountry": "Brazil"}]}}, "ReferencesModule": {"ReferenceList": {"Reference": [{"ReferencePMID": "19158356", "ReferenceType": "background", "ReferenceCitation": "Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629-37. doi: 10.1681/ASN.2008030287. Epub 2009 Jan 21."}]}}}, "ResultsSection": {"ParticipantFlowModule": {"FlowPreAssignmentDetails": "Safety Population: All participants who received at least 1 dose of RP103.", "FlowGroupList": {"FlowGroup": [{"FlowGroupId": "FG000", "FlowGroupTitle": "RP103", "FlowGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "FlowPeriodList": {"FlowPeriod": [{"FlowPeriodTitle": "Overall Study", "FlowMilestoneList": {"FlowMilestone": [{"FlowMilestoneType": "STARTED", "FlowAchievementList": {"FlowAchievement": [{"FlowAchievementGroupId": "FG000", "FlowAchievementNumSubjects": "17"}]}}, {"FlowMilestoneType": "COMPLETED", "FlowAchievementList": {"FlowAchievement": [{"FlowAchievementGroupId": "FG000", "FlowAchievementNumSubjects": "16"}]}}, {"FlowMilestoneType": "NOT COMPLETED", "FlowAchievementList": {"FlowAchievement": [{"FlowAchievementGroupId": "FG000", "FlowAchievementNumSubjects": "1"}]}}]}, "FlowDropWithdrawList": {"FlowDropWithdraw": [{"FlowDropWithdrawType": "Death", "FlowReasonList": {"FlowReason": [{"FlowReasonGroupId": "FG000", "FlowReasonNumSubjects": "1"}]}}]}}]}}, "BaselineCharacteristicsModule": {"BaselinePopulationDescription": "Safety Population: All participants who received at least 1 dose of RP103.", "BaselineGroupList": {"BaselineGroup": [{"BaselineGroupId": "BG000", "BaselineGroupTitle": "RP103", "BaselineGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "BaselineDenomList": {"BaselineDenom": [{"BaselineDenomUnits": "Participants", "BaselineDenomCountList": {"BaselineDenomCount": [{"BaselineDenomCountGroupId": "BG000", "BaselineDenomCountValue": "17"}]}}]}, "BaselineMeasureList": {"BaselineMeasure": [{"BaselineMeasureTitle": "Age, Continuous", "BaselineMeasureParamType": "Mean", "BaselineMeasureDispersionType": "Standard Deviation", "BaselineMeasureUnitOfMeasure": "years", "BaselineClassList": {"BaselineClass": [{"BaselineCategoryList": {"BaselineCategory": [{"BaselineMeasurementList": {"BaselineMeasurement": [{"BaselineMeasurementGroupId": "BG000", "BaselineMeasurementValue": "3.80", "BaselineMeasurementSpread": "5.116"}]}}]}}]}}, {"BaselineMeasureTitle": "Sex: Female, Male", "BaselineMeasureParamType": "Count of Participants", "BaselineMeasureUnitOfMeasure": "Participants", "BaselineClassList": {"BaselineClass": [{"BaselineCategoryList": {"BaselineCategory": [{"BaselineCategoryTitle": "Female", "BaselineMeasurementList": {"BaselineMeasurement": [{"BaselineMeasurementGroupId": "BG000", "BaselineMeasurementValue": "7"}]}}, {"BaselineCategoryTitle": "Male", "BaselineMeasurementList": {"BaselineMeasurement": [{"BaselineMeasurementGroupId": "BG000", "BaselineMeasurementValue": "10"}]}}]}}]}}]}}, "OutcomeMeasuresModule": {"OutcomeMeasureList": {"OutcomeMeasure": [{"OutcomeMeasureType": "Primary", "OutcomeMeasureTitle": "Mean White Blood Cell (WBC) Cystine Concentration at Each Visit", "OutcomeMeasureDescription": "Blood samples were taken 30 minutes after the morning RP103 dose at each study visit to determine White Blood Cell (WBC) cystine concentration. WBC cystine concentrations were determined using liquid chromatography.", "OutcomeMeasurePopulationDescription": "Participants <6 years of age who received at least 1 dose of RP103 and who had at least 1 WBC cystine level recorded.", "OutcomeMeasureReportingStatus": "Posted", "OutcomeMeasureParamType": "Mean", "OutcomeMeasureDispersionType": "Standard Deviation", "OutcomeMeasureUnitOfMeasure": "nmol 1/2 Cystine/mg protein", "OutcomeMeasureTimeFrame": "Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Month 6, Month 9, Month 12, Month 15, Month 18, Study Exit", "OutcomeGroupList": {"OutcomeGroup": [{"OutcomeGroupId": "OG000", "OutcomeGroupTitle": "RP103", "OutcomeGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "OutcomeDenomList": {"OutcomeDenom": [{"OutcomeDenomUnits": "Participants", "OutcomeDenomCountList": {"OutcomeDenomCount": [{"OutcomeDenomCountGroupId": "OG000", "OutcomeDenomCountValue": "15"}]}}]}, "OutcomeClassList": {"OutcomeClass": [{"OutcomeClassTitle": "Day 1", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "15"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "3.1709", "OutcomeMeasurementSpread": "2.95209"}]}}]}}, {"OutcomeClassTitle": "Week 2", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "15"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "2.2899", "OutcomeMeasurementSpread": "3.13707"}]}}]}}, {"OutcomeClassTitle": "Week 4", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "13"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "1.8474", "OutcomeMeasurementSpread": "1.62820"}]}}]}}, {"OutcomeClassTitle": "Week 6", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "13"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "2.3403", "OutcomeMeasurementSpread": "4.31136"}]}}]}}, {"OutcomeClassTitle": "Week 8", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "13"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "0.9589", "OutcomeMeasurementSpread": "1.05851"}]}}]}}, {"OutcomeClassTitle": "Week 10", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "12"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "1.1219", "OutcomeMeasurementSpread": "1.27413"}]}}]}}, {"OutcomeClassTitle": "Week 12", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "13"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "1.1828", "OutcomeMeasurementSpread": "1.31272"}]}}]}}, {"OutcomeClassTitle": "Month 6", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "2"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "2.7250", "OutcomeMeasurementSpread": "1.08187"}]}}]}}, {"OutcomeClassTitle": "Month 9", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "6"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "2.0196", "OutcomeMeasurementSpread": "1.90931"}]}}]}}, {"OutcomeClassTitle": "Month 12", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "13"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "0.8012", "OutcomeMeasurementSpread": "0.59706"}]}}]}}, {"OutcomeClassTitle": "Month 15", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "9"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "1.2443", "OutcomeMeasurementSpread": "1.47616"}]}}]}}, {"OutcomeClassTitle": "Month 18", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "9"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "0.7356", "OutcomeMeasurementSpread": "0.64027"}]}}]}}, {"OutcomeClassTitle": "Study Exit", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "13"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "0.8197", "OutcomeMeasurementSpread": "0.76413"}]}}]}}]}}, {"OutcomeMeasureType": "Secondary", "OutcomeMeasureTitle": "Number of Participants With Adverse Events", "OutcomeMeasureDescription": "Safety was assessed by the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). An AE/adverse experience was any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. For additional information regarding adverse events, please see the safety section of the record.", "OutcomeMeasurePopulationDescription": "Safety population: All participants who received at least 1 dose of RP103.", "OutcomeMeasureReportingStatus": "Posted", "OutcomeMeasureParamType": "Count of Participants", "OutcomeMeasureUnitOfMeasure": "Participants", "OutcomeMeasureTimeFrame": "Day 1 through study exit", "OutcomeGroupList": {"OutcomeGroup": [{"OutcomeGroupId": "OG000", "OutcomeGroupTitle": "RP103", "OutcomeGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "OutcomeDenomList": {"OutcomeDenom": [{"OutcomeDenomUnits": "Participants", "OutcomeDenomCountList": {"OutcomeDenomCount": [{"OutcomeDenomCountGroupId": "OG000", "OutcomeDenomCountValue": "17"}]}}]}, "OutcomeClassList": {"OutcomeClass": [{"OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "17"}]}}]}}]}}, {"OutcomeMeasureType": "Secondary", "OutcomeMeasureTitle": "Maximum Observed Plasma Concentration (Cmax) of Cysteamine", "OutcomeMeasureDescription": "Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. The maximum observed plasma concentration (Cmax) of cysteamine was determined directly from the data.", "OutcomeMeasurePopulationDescription": "Participants age <6 years who received at least 1 dose of RP103 and participated in frequent sampling at the Month 6 visit.", "OutcomeMeasureReportingStatus": "Posted", "OutcomeMeasureParamType": "Mean", "OutcomeMeasureDispersionType": "Standard Deviation", "OutcomeMeasureUnitOfMeasure": "mg/L", "OutcomeMeasureTimeFrame": "30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later", "OutcomeGroupList": {"OutcomeGroup": [{"OutcomeGroupId": "OG000", "OutcomeGroupTitle": "RP103", "OutcomeGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "OutcomeDenomList": {"OutcomeDenom": [{"OutcomeDenomUnits": "Participants", "OutcomeDenomCountList": {"OutcomeDenomCount": [{"OutcomeDenomCountGroupId": "OG000", "OutcomeDenomCountValue": "11"}]}}]}, "OutcomeClassList": {"OutcomeClass": [{"OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "1.26", "OutcomeMeasurementSpread": "0.86"}]}}]}}]}}, {"OutcomeMeasureType": "Secondary", "OutcomeMeasureTitle": "Time of the Maximum Observed Plasma Concentration (Tmax) of Cysteamine", "OutcomeMeasureDescription": "Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. The time of the maximum observed plasma concentration (Tmax) of cysteamine was determined directly from the data.", "OutcomeMeasurePopulationDescription": "Participants age <6 years who received at least 1 dose of RP103 and participated in frequent sampling at the Month 6 visit.", "OutcomeMeasureReportingStatus": "Posted", "OutcomeMeasureParamType": "Mean", "OutcomeMeasureDispersionType": "Standard Deviation", "OutcomeMeasureUnitOfMeasure": "minutes", "OutcomeMeasureTimeFrame": "30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later", "OutcomeGroupList": {"OutcomeGroup": [{"OutcomeGroupId": "OG000", "OutcomeGroupTitle": "RP103", "OutcomeGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "OutcomeDenomList": {"OutcomeDenom": [{"OutcomeDenomUnits": "Participants", "OutcomeDenomCountList": {"OutcomeDenomCount": [{"OutcomeDenomCountGroupId": "OG000", "OutcomeDenomCountValue": "11"}]}}]}, "OutcomeClassList": {"OutcomeClass": [{"OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "199", "OutcomeMeasurementSpread": "138"}]}}]}}]}}, {"OutcomeMeasureType": "Secondary", "OutcomeMeasureTitle": "Area Under the Plasma Concentration Versus Time Curve (AUC) of Cysteamine", "OutcomeMeasureDescription": "Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. AUC values were estimated using non-compartmental analysis methods. AUClast was defined as the area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (720 minutes). AUCinf was defined as the area under the plasma concentration-versus-time curve from time 0 to infinity.", "OutcomeMeasurePopulationDescription": "Participants age <6 years who received at least 1 dose of RP103 and participated in frequent sampling at the Month 6 visit.", "OutcomeMeasureReportingStatus": "Posted", "OutcomeMeasureParamType": "Mean", "OutcomeMeasureDispersionType": "Standard Deviation", "OutcomeMeasureUnitOfMeasure": "min*mg/L", "OutcomeMeasureTimeFrame": "30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later", "OutcomeGroupList": {"OutcomeGroup": [{"OutcomeGroupId": "OG000", "OutcomeGroupTitle": "RP103", "OutcomeGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules."}]}, "OutcomeDenomList": {"OutcomeDenom": [{"OutcomeDenomUnits": "Participants", "OutcomeDenomCountList": {"OutcomeDenomCount": [{"OutcomeDenomCountGroupId": "OG000", "OutcomeDenomCountValue": "11"}]}}]}, "OutcomeClassList": {"OutcomeClass": [{"OutcomeClassTitle": "AUClast", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "11"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "206", "OutcomeMeasurementSpread": "113"}]}}]}}, {"OutcomeClassTitle": "AUCinf", "OutcomeClassDenomList": {"OutcomeClassDenom": [{"OutcomeClassDenomUnits": "Participants", "OutcomeClassDenomCountList": {"OutcomeClassDenomCount": [{"OutcomeClassDenomCountGroupId": "OG000", "OutcomeClassDenomCountValue": "10"}]}}]}, "OutcomeCategoryList": {"OutcomeCategory": [{"OutcomeMeasurementList": {"OutcomeMeasurement": [{"OutcomeMeasurementGroupId": "OG000", "OutcomeMeasurementValue": "231", "OutcomeMeasurementSpread": "123"}]}}]}}]}}]}}, "AdverseEventsModule": {"EventsFrequencyThreshold": "0", "EventsTimeFrame": "From Day 1 through study exit", "EventsDescription": "Adverse events (AEs) were defined as any AE with onset following initial drug administration (on Day 1).", "EventGroupList": {"EventGroup": [{"EventGroupId": "EG000", "EventGroupTitle": "RP103", "EventGroupDescription": "From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.", "EventGroupDeathsNumAffected": "1", "EventGroupDeathsNumAtRisk": "17", "EventGroupSeriousNumAffected": "12", "EventGroupSeriousNumAtRisk": "17", "EventGroupOtherNumAffected": "16", "EventGroupOtherNumAtRisk": "17"}]}, "SeriousEventList": {"SeriousEvent": [{"SeriousEventTerm": "Gastroenteritis", "SeriousEventOrganSystem": "Infections and infestations", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "5", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Catheter Site Infection", "SeriousEventOrganSystem": "Infections and infestations", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Clostridium difficile Colitis", "SeriousEventOrganSystem": "Infections and infestations", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Gastroenteritis Viral", "SeriousEventOrganSystem": "Infections and infestations", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Dehydration", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "4", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Electrolyte Imbalance", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "2", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Failure to Thrive", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Hypernatraemia", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Hypocalcaemia", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Malnutrition", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Metabolic Acidosis", "SeriousEventOrganSystem": "Metabolism and nutrition disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Vomiting", "SeriousEventOrganSystem": "Gastrointestinal disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "4", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Abdominal Distension", "SeriousEventOrganSystem": "Gastrointestinal disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Gastrostomy", "SeriousEventOrganSystem": "Surgical and medical procedures", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "2", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Anaemia", "SeriousEventOrganSystem": "Blood and lymphatic system disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Cardiopulmonary Failure", "SeriousEventOrganSystem": "Cardiac disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Fanconi Syndrome", "SeriousEventOrganSystem": "Congenital, familial and genetic disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}, {"SeriousEventTerm": "Hypovolaemic Shock", "SeriousEventOrganSystem": "Vascular disorders", "SeriousEventSourceVocabulary": "MedDRA (16.1)", "SeriousEventAssessmentType": "Systematic Assessment", "SeriousEventStatsList": {"SeriousEventStats": [{"SeriousEventStatsGroupId": "EG000", "SeriousEventStatsNumAffected": "1", "SeriousEventStatsNumAtRisk": "17"}]}}]}, "OtherEventList": {"OtherEvent": [{"OtherEventTerm": "Vomiting", "OtherEventOrganSystem": "Gastrointestinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "12", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Diarrhoea", "OtherEventOrganSystem": "Gastrointestinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "6", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Breath Odour", "OtherEventOrganSystem": "Gastrointestinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "4", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Nausea", "OtherEventOrganSystem": "Gastrointestinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "3", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Abdominal Pain", "OtherEventOrganSystem": "Gastrointestinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Upper Respiratory Tract Infection", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "8", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Gastroenteritis", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "3", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Rhinitis", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "3", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Catheter Site Infection", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Otitis Media", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Pharyngitis", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Sinusitis", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Varicella", "OtherEventOrganSystem": "Infections and infestations", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Pyrexia", "OtherEventOrganSystem": "General disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "4", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Granuloma", "OtherEventOrganSystem": "General disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Medical Device Site Reaction", "OtherEventOrganSystem": "General disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Cough", "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "4", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Rhinorrhoea", "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "2", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Epistaxis", "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Decreased Appetite", "OtherEventOrganSystem": "Metabolism and nutrition disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Hypernatraemia", "OtherEventOrganSystem": "Metabolism and nutrition disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Hypokalaemia", "OtherEventOrganSystem": "Metabolism and nutrition disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Malnutrition", "OtherEventOrganSystem": "Metabolism and nutrition disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Conjunctivitis", "OtherEventOrganSystem": "Eye disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Strabismus", "OtherEventOrganSystem": "Eye disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Headache", "OtherEventOrganSystem": "Nervous system disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "2", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Dermatitis Diaper", "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "2", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Gastrostomy Closure", "OtherEventOrganSystem": "Surgical and medical procedures", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Gastrostomy Tube Removal", "OtherEventOrganSystem": "Surgical and medical procedures", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Anaemia", "OtherEventOrganSystem": "Blood and lymphatic system disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Foot Deformity", "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Perineal Erythema", "OtherEventOrganSystem": "Reproductive system and breast disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}, {"OtherEventTerm": "Hypertension", "OtherEventOrganSystem": "Vascular disorders", "OtherEventSourceVocabulary": "MedDRA (16.1)", "OtherEventAssessmentType": "Systematic Assessment", "OtherEventStatsList": {"OtherEventStats": [{"OtherEventStatsGroupId": "EG000", "OtherEventStatsNumAffected": "1", "OtherEventStatsNumAtRisk": "17"}]}}]}}, "MoreInfoModule": {"CertainAgreement": {"AgreementPISponsorEmployee": "No", "AgreementRestrictionType": "OTHER", "AgreementRestrictiveAgreement": "Yes", "AgreementOtherDetails": "Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights ."}, "PointOfContact": {"PointOfContactTitle": "Evelyn Olson, Director", "PointOfContactOrganization": "Horizon Pharma USA, Inc.", "PointOfContactEMail": "clinicaltrials@horizonpharma.com", "PointOfContactPhone": "224-383-3000"}}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000003554", "ConditionMeshTerm": "Cystinosis"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000016464", "ConditionAncestorTerm": "Lysosomal Storage Diseases"}, {"ConditionAncestorId": "D000008661", "ConditionAncestorTerm": "Metabolism, Inborn Errors"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}, {"ConditionAncestorId": "D000008659", "ConditionAncestorTerm": "Metabolic Diseases"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M5911", "ConditionBrowseLeafName": "Cystinosis", "ConditionBrowseLeafAsFound": "Cystinosis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M7493", "ConditionBrowseLeafName": "Fanconi Syndrome", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M18023", "ConditionBrowseLeafName": "Lysosomal Storage Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M10793", "ConditionBrowseLeafName": "Metabolism, Inborn Errors", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M10791", "ConditionBrowseLeafName": "Metabolic Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T1714", "ConditionBrowseLeafName": "Cystinosis", "ConditionBrowseLeafAsFound": "Cystinosis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "T2272", "ConditionBrowseLeafName": "Fanconi Syndrome", "ConditionBrowseLeafRelevance": "low"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "BC18", "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BXS", "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}, "InterventionBrowseModule": {"InterventionMeshList": {"InterventionMesh": [{"InterventionMeshId": "D000003543", "InterventionMeshTerm": "Cysteamine"}]}, "InterventionAncestorList": {"InterventionAncestor": [{"InterventionAncestorId": "D000065104", "InterventionAncestorTerm": "Cystine Depleting Agents"}, {"InterventionAncestorId": "D000045504", "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"}]}, "InterventionBrowseLeafList": {"InterventionBrowseLeaf": [{"InterventionBrowseLeafId": "M5900", "InterventionBrowseLeafName": "Cysteamine", "InterventionBrowseLeafAsFound": "Concurrent Chemoradiation", "InterventionBrowseLeafRelevance": "high"}]}, "InterventionBrowseBranchList": {"InterventionBrowseBranch": [{"InterventionBrowseBranchAbbrev": "All", "InterventionBrowseBranchName": "All Drugs and Chemicals"}]}}}}}, {"Rank": 10, "Study": {"ProtocolSection": {"IdentificationModule": {"NCTId": "NCT02280135", "OrgStudyIdInfo": {"OrgStudyId": "TC/RP"}, "SecondaryIdInfoList": {"SecondaryIdInfo": [{"SecondaryId": "2012-000618-12", "SecondaryIdType": "EudraCT Number"}]}, "Organization": {"OrgFullName": "Red de Terapia Celular", "OrgClass": "INDUSTRY"}, "BriefTitle": "Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa", "OfficialTitle": "Phase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa", "Acronym": "TC/RP"}, "StatusModule": {"StatusVerifiedDate": "March 2017", "OverallStatus": "Completed", "ExpandedAccessInfo": {"HasExpandedAccess": "No"}, "StartDateStruct": {"StartDate": "November 2014"}, "PrimaryCompletionDateStruct": {"PrimaryCompletionDate": "March 2017", "PrimaryCompletionDateType": "Actual"}, "CompletionDateStruct": {"CompletionDate": "March 2017", "CompletionDateType": "Actual"}, "StudyFirstSubmitDate": "October 22, 2014", "StudyFirstSubmitQCDate": "October 29, 2014", "StudyFirstPostDateStruct": {"StudyFirstPostDate": "October 31, 2014", "StudyFirstPostDateType": "Estimate"}, "LastUpdateSubmitDate": "March 29, 2017", "LastUpdatePostDateStruct": {"LastUpdatePostDate": "March 30, 2017", "LastUpdatePostDateType": "Actual"}}, "SponsorCollaboratorsModule": {"ResponsibleParty": {"ResponsiblePartyType": "Sponsor"}, "LeadSponsor": {"LeadSponsorName": "Red de Terapia Celular", "LeadSponsorClass": "INDUSTRY"}, "CollaboratorList": {"Collaborator": [{"CollaboratorName": "Spanish National Health System", "CollaboratorClass": "OTHER"}, {"CollaboratorName": "Hospital Universitario Virgen de la Arrixaca", "CollaboratorClass": "OTHER"}, {"CollaboratorName": "Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia", "CollaboratorClass": "OTHER"}, {"CollaboratorName": "Public Health Service, Murcia", "CollaboratorClass": "OTHER"}, {"CollaboratorName": "Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca", "CollaboratorClass": "OTHER"}]}}, "OversightModule": {"OversightHasDMC": "Yes"}, "DescriptionModule": {"BriefSummary": "The purpose of this study is to evaluate the safety of intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa by a prospective, single-center, randomized, parallel, double-blind, phase I placebo-controlled clinical trial."}, "ConditionsModule": {"ConditionList": {"Condition": ["Retinitis Pigmentosa"]}}, "DesignModule": {"StudyType": "Interventional", "PhaseList": {"Phase": ["Phase 1"]}, "DesignInfo": {"DesignAllocation": "Randomized", "DesignInterventionModel": "Parallel Assignment", "DesignPrimaryPurpose": "Treatment", "DesignMaskingInfo": {"DesignMasking": "Double", "DesignWhoMaskedList": {"DesignWhoMasked": ["Participant", "Investigator"]}}}, "EnrollmentInfo": {"EnrollmentCount": "8", "EnrollmentType": "Actual"}}, "ArmsInterventionsModule": {"ArmGroupList": {"ArmGroup": [{"ArmGroupLabel": "Intravitreal injection of Autologous bone marrow Stem Cell", "ArmGroupType": "Experimental", "ArmGroupDescription": "Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.\n\nThe average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Biological: Intravitreal injection of Autologous bone marrow Stem Cell"]}}, {"ArmGroupLabel": "Subconjunctival injection of saline", "ArmGroupType": "Placebo Comparator", "ArmGroupDescription": "Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.", "ArmGroupInterventionList": {"ArmGroupInterventionName": ["Other: Subconjunctival injection of saline"]}}]}, "InterventionList": {"Intervention": [{"InterventionType": "Biological", "InterventionName": "Intravitreal injection of Autologous bone marrow Stem Cell", "InterventionDescription": "We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.\n\nAfter the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.\n\nAfter injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Intravitreal injection of Autologous bone marrow Stem Cell"]}}, {"InterventionType": "Other", "InterventionName": "Subconjunctival injection of saline", "InterventionDescription": "In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.\n\nAfter injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.", "InterventionArmGroupLabelList": {"InterventionArmGroupLabel": ["Subconjunctival injection of saline"]}}]}}, "OutcomesModule": {"PrimaryOutcomeList": {"PrimaryOutcome": [{"PrimaryOutcomeMeasure": "Rate of serious and non-serious adverse events related with the use of bone marrow mononuclear cells in patients with retinitis pigmentosa", "PrimaryOutcomeTimeFrame": "12 months from baseline"}]}, "SecondaryOutcomeList": {"SecondaryOutcome": [{"SecondaryOutcomeMeasure": "Quality of Life: Questionnaire VFQ-25 (Visual Function Questionnaire-25).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Visual acuity (VA): Test ETDRS (Early Treatment Diabetic Retinopathy Study).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Color Vision: Ishihara Color Test.", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Contrast sensitivity: CSV-1000E.", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Intraocular pressure (IOP): measured in mm Hg with applanation tonometer Haag Streit AT 900.", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Examination of the anterior and posterior pole: Made with biomicroscopy (BMC).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Width of retinal macula layer and nerve fiber: Measured with Optical Coherence Tomography Spectral domain (OCT)(Topcon 3D OCT-2000 Spectral Domain OCT).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Visual field (VF) and macular sensitivity (The Humphrey perimeter).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Study eye fundus: Made by Retinography and Angiography fluorescein.", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Electrical retinal function: electroretinogram (ERG) (altered / unaltered).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}, {"SecondaryOutcomeMeasure": "Visual evoked potentials with Pattern Reversal (VEP) (altered / no altered).", "SecondaryOutcomeTimeFrame": "12 months from baseline"}]}}, "EligibilityModule": {"EligibilityCriteria": "Inclusion Criteria:\n\nRetinitis Pigmentosa bilateral diagnosis.\nVisual acuity (measured with ETDRS) less than or equal to 20/70 and visual field below 30\u00b0 central in both eyes.\nSigned informed consent\nWarranty sufficient adherence to protocol. It must fulfill all inclusion criteria.\n\nExclusion Criteria:\n\nConcurrence of any systemic or ocular disease that precludes or affects tracking study variables. Specifically retinal involvement with diabetes mellitus, glaucoma, macular degeneration or age.\nEye surgery in the previous 6 months.\nPatients who are pregnant.\nPatients with active lactation.\nPhysically fertile patients, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle or sexual orientation excludes sexual intercourse with a man and women whose partners have been sterilized by vasectomy or other methods, UNLESS tHEY are using a reliable contraceptive method. This birth control method can be:\nComplete abstinence from sexual intercourse\nSurgical sterilization (tubal ligation)\nSurgical sterilization partner (vasectomy)\nImplanted or injectable hormonal contraceptives and oral.\nPatients with cardiac disease, renal, hepatic, systemic, immune that might influence the survival of patients during the test.\nPositive serology for hepatitis B, hepatitis C or HIV.\nClinical criteria or anesthetics that contraindicate the sedation or the extraction of BM (Altered coagulation system or anticoagulated patient with inability to withdraw anticoagulation, hemodynamic instability, altered skin in the puncture site, etc.)\nParticipation in other clinical trials.\nInability to sign informed consent or understanding.", "HealthyVolunteers": "No", "Gender": "All", "MinimumAge": "18 Years", "MaximumAge": "70 Years", "StdAgeList": {"StdAge": ["Adult", "Older Adult"]}}, "ContactsLocationsModule": {"OverallOfficialList": {"OverallOfficial": [{"OverallOfficialName": "Mar\u00eda Elena Rodriguez Gonz\u00e1lez-Herrero, MD", "OverallOfficialAffiliation": "Hospital Universitario Virgen de la Arrixaca", "OverallOfficialRole": "Principal Investigator"}]}, "LocationList": {"Location": [{"LocationFacility": "Clinical Universitary Hospital Virgen de la Arrixaca", "LocationCity": "El Palmar", "LocationState": "Murcia", "LocationZip": "30120", "LocationCountry": "Spain"}]}}}, "DerivedSection": {"MiscInfoModule": {"VersionHolder": "May 12, 2023"}, "ConditionBrowseModule": {"ConditionMeshList": {"ConditionMesh": [{"ConditionMeshId": "D000012173", "ConditionMeshTerm": "Retinitis"}, {"ConditionMeshId": "D000012174", "ConditionMeshTerm": "Retinitis Pigmentosa"}]}, "ConditionAncestorList": {"ConditionAncestor": [{"ConditionAncestorId": "D000012164", "ConditionAncestorTerm": "Retinal Diseases"}, {"ConditionAncestorId": "D000005128", "ConditionAncestorTerm": "Eye Diseases"}, {"ConditionAncestorId": "D000015785", "ConditionAncestorTerm": "Eye Diseases, Hereditary"}, {"ConditionAncestorId": "D000058499", "ConditionAncestorTerm": "Retinal Dystrophies"}, {"ConditionAncestorId": "D000012162", "ConditionAncestorTerm": "Retinal Degeneration"}, {"ConditionAncestorId": "D000030342", "ConditionAncestorTerm": "Genetic Diseases, Inborn"}]}, "ConditionBrowseLeafList": {"ConditionBrowseLeaf": [{"ConditionBrowseLeafId": "M14160", "ConditionBrowseLeafName": "Retinitis", "ConditionBrowseLeafAsFound": "Retinitis", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14161", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}, {"ConditionBrowseLeafId": "M14151", "ConditionBrowseLeafName": "Retinal Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M7423", "ConditionBrowseLeafName": "Eye Diseases", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M17491", "ConditionBrowseLeafName": "Eye Diseases, Hereditary", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M28260", "ConditionBrowseLeafName": "Retinal Dystrophies", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M14149", "ConditionBrowseLeafName": "Retinal Degeneration", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "M22839", "ConditionBrowseLeafName": "Genetic Diseases, Inborn", "ConditionBrowseLeafRelevance": "low"}, {"ConditionBrowseLeafId": "T4945", "ConditionBrowseLeafName": "Retinitis Pigmentosa", "ConditionBrowseLeafAsFound": "Retinitis Pigmentosa", "ConditionBrowseLeafRelevance": "high"}]}, "ConditionBrowseBranchList": {"ConditionBrowseBranch": [{"ConditionBrowseBranchAbbrev": "BC11", "ConditionBrowseBranchName": "Eye Diseases"}, {"ConditionBrowseBranchAbbrev": "All", "ConditionBrowseBranchName": "All Conditions"}, {"ConditionBrowseBranchAbbrev": "BC16", "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"}, {"ConditionBrowseBranchAbbrev": "Rare", "ConditionBrowseBranchName": "Rare Diseases"}]}}, "InterventionBrowseModule": {"InterventionBrowseLeafList": {"InterventionBrowseLeaf": [{"InterventionBrowseLeafId": "M16235", "InterventionBrowseLeafName": "Tropicamide", "InterventionBrowseLeafRelevance": "low"}]}, "InterventionBrowseBranchList": {"InterventionBrowseBranch": [{"InterventionBrowseBranchAbbrev": "All", "InterventionBrowseBranchName": "All Drugs and Chemicals"}]}}}}}]}}